Viral infections are usually treated with substances targeting viral proteins. For example, influenza is treated with M2-membrane protein inhibitors (adamantin and rimantadin) or neuraminidase inhibitors (oseltamivir and zanamivir). HIV is treated with HIV protease inhibitors, reverse transcriptase inhibitors (nucleoside and non-nuc!eoside analoga), fusion inhibitors (blocking the viral transmembrane protein gp41 ) or cell entry inhibitors. HCV is usually treated by a combination of ribavirin and interferone alpha, where ribavirin as a nucleoside analogue inhibits the viral polymerase and interferone alpha activates the host immune system; also viral protease inhibitors and viral RNA polymerase inhibitors have been recently approved for treatment. HBV is treated with pegylated interferone alpha and/or nucleoside or nucleotide analoga. Herpes and human cytomegalovirus infections are treated with ganciclovir or structurally related substances like acyclovir and penciclovir, respectively, which also are analogs of the nuclein base guanine. However, these approaches to the treatment of viral diseases are not satisfactory due to the high mutation rate of viruses and the thus resulting lack of efficacy of presently known medications. Moreover, severe side effects caused by interaction with host factors or by incompatibility of treatments for patients who are infected with two or several different viruses occur regularly. In view of rising numbers of infections, especially with opportunistic viruses like HSV and HCMV in the background of immunocompromised patients (e.g organ transplant recipients or HIV infected persons) and taking into account the viruses' abilities to quickly adapt to new selection pressures caused by substances targeting viral proteins, new treatment options for viral diseases are urgently required. A rarely used approach to circumvent the selection pressure on viruses and thus avoid the generation of resistences is the targeting of host cell factors vital for the viral replication cycle. An example for inhibition of host: targets constitutes the small molecule CLK inhibitor TG003 ((Z)-l -(3-Ethyl-5-methoxy-2,3- dihydrobenzothiazol-2-ylidene)propan-2-one). TG003 has been tested against influenza viruses i in vitro assays and its activity was attributed to its interference with the splicing of viral M2 messanger RNA (Karlas A et al. (2010) Nature 463, 818-822). In this way, the cellular machinery required for production of virus progeny is inhibited and thus can be exploited to suppress the replication of certain viruses. However, Karlas A et al (Nature (2010) 463, 818-822) tested TG003 in a viral model and found that TG003 inhibited viral replication by about only one order of magnitude at a concentration of about 50μΜ, thus rendering this compound unsuitable for effectively treating subjects suffering from viral infections. Even a complete knockdown of CLK1 did not stop viral replication entirely. These results indicate that inhibition of CI.K 1 alone is insufficient to inhibit viral replication.

WO 2014/202638 Al describes certain compounds of the present Formula. (I) and that they interact with DYRK kinase, suggesting their applicability in prevention and/or therapy o medical conditions wherein the function o DYRK kinase plays a role.

BRIEF SUMMARY OF THE INVENTION

It has now been found that the compounds of below Formula (I) surprisingly also display activity against certain viruses. Moreover, said compounds show inhibition of viral replication, although the entire mechnism by which said inhibition is achieved is currently not known.

In one aspect, the present invention therefore provides methods for the treatment or prevention of medical conditions involving viral infections, the method comprising the administration of compounds of Formula (I), physiologically functional derivatives or salts thereof, to a subject in need thereof, as detailed further herein below.

In another aspect, the present invention provides the use of compounds of Formula (I), physiologically functional derivatives or salts thereof, in the manufacture of a medicament for the treatment or prevention of medical conditions involving viral infections, as detailed further herein below. In another aspect, the present invention provides compounds of Formula (I), physiologically functional derivatives or salts thereof, for use in the treatment or prevention of medical conditions involving viral infections, as detailed further herein below.

Said compounds are particularly advantageous for the treatment or prevention of diseases caused by viral infections, more particularly herpes viridae, even more particularly by one of the following viruses: Human Cytomegalo Virus (HCMV) and Herpes Simplex Virus (HSV). In another aspect, the present invention provides phannaceutical compositions comprising compounds of Formula (I), physiologically functional derivatives or salts thereof and one or more pharmaceutically acceptable excipients for the above medicinal purposes.

Said compounds of Formula (I) arc shown below, and the groups R ¹ , R\ R\ R ⁴ , R ^A , X ¹ and A, as well as the integers n, m and p are detailed further herein below.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the impact of DYRK. activity on HCMV replication. Compounds were analyzed by a GFP-based replication assay using HCMV AD169-GFP for the infection of HFFs (MOI of 0.01 , uninfected control, Mock). Antiviral compounds were added immediately post-infection at the concentrations indicated (reference drug ganciclovir - GCV, 20 μΜ). Cells were lysed seven days post-infection to perform quantitative GFP fluorometry (n = 4, mean SD).

DETAILED DESCRIPTION OF THE INVENTION

Embodiments of the present invention are enumerated in the following items:

1. A compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof for the use in the treatment or prevention of a disease or medical condition caused by a viral infection,

wherein the X'-azol moiety is attached at the 5- or 6- position of the 2,3- dihydrobenzofuran mioety. n is an integer from 0 to 2;

m is an integer from 0 to 3;

p is an integer from 0 to 4;

R ¹ is independently selected from the group comprising H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy. -CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -S-R-, -SO-R ^" , nitro, -NH ₂ . -N(R ^* ) ₂ , -NH(R'), -NHCO(R'), -CONH ₂ , -CONH(R'), -CO(R'), -COH, -COO(R'), -COOH, -S0 ₂ NH ₂ , -S0 ₂ NH(R ^" ), -S0 ₂ (R ^" ). -NH-S0 ₂ (R ^" ) and -NHCOOR ^" :

R ² is independently selected from the group comprising H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, -CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -S-R\ -SO-R-, nitro, -NH , -N(R') ₂ , -NH(R'), -NHCO(R'), -CONH ₂ , -CONH(R ) -CO(R'), -COH, -COO(R'), -COOH, -S0 ₂ NH ₂ , -S0 ₂ NH(R ^" ). -S0 ₂ (R ^' ). -NH-S0 ₂ (R') and -NHCOOR';

R ³ is independently selected from the group comprising H. halogen, alkyl, aralkyl, haloalkyl haloalkoxy, OH, alkoxy, -CN, aryl, heteroaryl, cycloalkyl. heterocycloalkyl, -S-R\ -SO-R', nitro. -N¾, -N(R') ₂ , -NH(R'), -NHCO(R'), -CONH ₂ , -CONH(R'), -CO(R'), -COH, -COO(R'), -COOH, -S0 ₂ NH ₂ , -S0 ₃ NH(R ^" ), -S0 ₂ (R\). -NH-S0 ₂ (R ^" ) and -NHCOOR';

R ⁴ is independently selected from the group comprising 11, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -CONH _2s -CONH(R'), -CO(R'), -COO(R'), and -S0 ₂ (R\); ¹ is independently selected from the group comprising NR", O or S;

R ⁿ is independently selected from the group comprising H, alkyl, aralkyl, haloalkyl. haloalkoxy. OH, alkoxy, aryl, heteroaryl, cycloalkyl. heterocycloalkyl, -CONH ₂ , -CONH(R'), -CO(R'), -COO(R'), and -S0 ₂ (R');

A is a monocyclic or bi cyclic heteroaromatic ring system consisting of 5 to 10 ring atoms, at least one of which is an N atom, wherein optionally one to three further ring atoms are heteroatoms independently selected from the group comprising O, S and N and wherein the remaining ring atoms are carbon atoms;

R ^A is independently selected from the group comprising H, halogen, CN, N0 ₂ , alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -OR ^* . -CO-R ^* . -COO-R ^* . -CONH-R ^' , -NHCO-R ^" , -CON(R') ₂ , -NR'CO-R', -NR'-CONR ^* . -NR'-COOR', -S-R\ -SO-R', -S0 ₂ -R\ -NHSO2-R ^* , -S0 ₂ NH-R\ -O-CO-NHR ^' , -O-CO-R ^" , -R'-O-R ^* . -R'-CO-R', -R'-NH-R', -R'-CONH-R', -R'-NHCO-R', -CONH-alkyl-O-R ^* . -CQNH- alkyl-R', -NHCO-alkyl-O-R ^" , -NHCO-alkyl-R', -CO-R'-alkyl-R', -CO-R'-alkyl, -S-alkyl-R ^' and lkyl-R ^" ; or in an alternative embodiment of item 1 , R ^A is independently selected from the group comprising H, halogen. CN, N0 ₂ , alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -OR ⁵ , -CO-R', -COO-R ^" , -CONH-R', -NHCO-R', -CON(R ) ₂ . -NR'CO-R', -NR'-CONR', -NR'-COOR', -S-R\ -SO-R ^" . -S0 ₂ -R\ -NHS0 ₂ -R ^" .

-SO ₂ NH-R', -O-CO-N H R ^* . -O-CO-R ^" . -R'-O-R', -R'-CO-R', -R'-NH-R', -R'-CONH- R', -R'-NHCO-R', -CONH-alkyl-O-R', -CONH-alkyl-R', -NHCO-alkyl-O-R', -NHCO-alkyl-R'. -CO-R'-alkyl-R', -CO-R'-alkyl, N(R') ₂ , -KHR ^" , NH ₂ , -S-R', -S- alkyi-R' and alkyl-R';

R' is independently selected from the group comprising H. alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl;

wherein any of the aforementioned alkyl. aryl. heteroaryl, cycloalkyl and heterocycloalkyl may independently be substituted with one or more, particularly one to three, more particularly one or two substituents R", wherein R" independently selected from the group comprising Ci_4-alkyl halogen, Ci ^-haloalkyl. OH, Ci _-4 - alkoxy, C,. ₄ -haloalkoxy, itro, -NH ₂ , -N(C -alkyl) ₂ , -NH(C |. ₄ -alkyl). -NHCO(Ci_ ₄ - alkyl). -CONH ₂ , -CONH(C _1-4 -alkyl), -CO(C _{1 -4} -alkyl), -COH, -COO(C -alkyl). -COOH and - CN.

The compound for the use according to above item 1 or a physiologically functional derivative, solvate or salt thereof, wherein

R ¹ is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, triiluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH ₂ , -N(methyl) ₂ , -NH-methyl, -NHCO-methyl. -CO I K -CONH-methyl, acetyl. -COO-mcthyl. and COOH; and

R ² is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, triiluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH ₂ , -N(methyl) ₂ , -NH-methyl, -NHCO-methyl, -CO H ₂ . -CONH-methyl, acetyl, -COO-methyl, and COOH.

The compound for the use according to the present invention, in particular according to above item I or 2 or a physiologically functional derivative, solvate or salt thereof, wherein n is 0 and m is 0.

The compound for the use according to the present invention, in particular according to any of the above items 1 to 3 or a physiologically functional derivative, solvate or salt thereof, wherein

R ³ is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, -OCF ₃ , OH, methoxy, ethoxy, -CN, nitro, -NH ₂ , -N(methyi) ₂ , -NH-methyl, -NHCO-methyl, -CONH ₂ , -CONH-methyl, acetyl, -COO-methyl, and -COOH.

The compound for the use according to the present invention, in particular according to any o the above items 1 to 4 or a physiologically functional derivative, solvate or salt thereof, wherein R ³ is I I. The compound for the use according to the present invention, in particular according to any of the above items 1 to 5 or a physiologically functional derivative, solvate or salt thereo , wherein

R ⁴ is independently selected from the group comprising I I, Ci _-3 -alkyl. Ci-4-haloalky], OIL -CONH ₂ , -CONH-C ,. ₃ -alkyi, -CO-C^-alkyl, and -COO-C _1-3 -alkyl.

The compound for the use according to the present invention, in particular according to any of the above items 1 to 6 or a physiologically functional derivative, solvate or salt thereof, wherein R ⁴ is 11.

The compound for the use according to any of the above items 1 to 7 or a physiologically functional derivative, solvate or salt thereof, wherein

A is a monocyclic heteroaromatic ring system consisting o 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms,

or in an alternative embodiment of item 8, A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms,

or one further ring atom is an O or S atom, or one further ring atom is an N atom and one ring atom is an O or S atom, and wherein the remaining ring atoms are carbon atoms; wherein A is optionally substituted with one or two substituents R ^A selected from the group comprising H, CN, NC½, halogen Oi l, alkoxy, haloalkyL alkyl, haloalkoxy, -COOH, -COO-alkyl, aralkyl, aryi, -CO-N(alkyl) ₂ , -CONH-(alkyl), -CONH-alkyl- alkoxy, -CONH-cycloalkyl, -C NH-alk yl -heterocycl oalk yl , -CO-heterocycloalkyl- alkyl-heterocycloalkyl, -CO-heterocycloalkyl, -S0 ₂ -alkyl, -S-alkyl, and -S-aralkyl, or in an alternative embodiment of item 8, A is optionally substituted with one or two substituents R ^A selected from the group comprising H, CN, N0 ₂ , NH ₂ , N(alkyl) ₂ , halogen OH, alkoxy, haloalkyl, alkyl, haloalkoxy, alkoxyalkyl, heterocycloalkyl, - heterocycloalkyl-alkyl, -heterocycloalkyl-COO-alkyl, heteroaryl, -COOH, -COO- alkyl, aralkyl, aryl. -aryl-halogen. -CO-N(alkyl) ₂ , -CONH-(aikyl), -CONH-alkyl- alkoxy, -CONH-cycloalkyl, -CONH-alkyl-heteroeycloalkyl, -CO-heterocycloalkyl- alkyl-heteroeycloalkyl, -CO-heterocycloalkyl, -CO-heteroaryl, -CO-aryl, -CO- alkyl, -S0 ₂ -alkyl, -S-alkyl, -S-alkyl-COO-alkyl. and -S-aralkyl.

The compound for the use according to any of the above items 1 to 8 or a physiologicall functional derivative, solvate or salt thereof, wherein

A is a monocyclic or bicyclic heteroaromatic ring system selected from the group comprising thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine, triazine, pyiimidine and pyridine, or in an alternative embodiment of item 9, A is a monocyclic or bicyclic heteroaromatic ring system selected from the group comprising thiazole. oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole. pyrazine, triazine, pyrimidinc, pyridine, thiadiazole, and oxadiazole, wherein A is optionally substituted with a substituent R ^A selected from the group comprising H, CN, F, CI, OH, C|. ₂ -alkoxy. CF ₃ , OCF ₃ , -COOH, -COO-(C|. ₂ -alkyl), benzyl, phenethyl, phenyl. -CO-N(C, _-2 -alkyl) ₂ , -CONH-(C,. ₂ -alkyl), -CO H-(C _{i 2} - alkyl)-0(Ci. ₂ -alkyl), -CONH-(C _3-5 -cycloalkyl), -CONH-(C , . ₂ -alkyl-tetrahydrofuryl), -CO-piperazinyl-(Ci. ₂ -alkyl)-tetrahydrofurany , -C -morholinyl. -CO-pyrrolidinyl, -CO-(methy] -pi peraziny )-. -S0 ₂ (Ci. ₂ -alkyl), -S-(Ci ,,-alkyl), -S-benzyl, -S-(chlorophenylmethyl), and -S-phenethyl, or in an alternative embodiment of item 9, A is optionally substituted with a substituent R ^A selected from the group comprising H, CN, F, CI, Br, OH. Cj ₂ -alkyl, C, . ₂ -alkoxy. CF ₃ , OCF ₃ , -COOH, -COO-(Ci. ₂ -alkyl), benzyl, phenethyl, phenyl, fluorophenyl, -CO-N(Ci_ ₂ -alkyl) ₂ , -CONH-(C, _-2 -alkyl), -CONH-(C , _-2 -alkyl)-0(C , . ₂ - alkyl), -CONH-(C _3-5 -cycloalkyl), -CONH-(C, _-2 -alkyl-tctrahydrofuryl), -CO- pipcrazinyl-(C i . ₂ -alkyl)-tctrahydrofuranyl. -CO-morholinyl, -CO-pyrrolidinyl, -CO- (methyl-piperazinyl)-. -S0 ₂ (Ci _-2 -alkyl), -S-(Ci _-4 -alkyl), -S-benzyl, -S- (chlorophenylmethyl), -S-phenethyl, -CO-thienyl, -CO-pyrrolyl, -CO-piperidinyl, -CO-piperidinyl-COO-(Ci.?-alkyl), morpholinyl, C i _-2 -alkylpipera/.inyl , C] _-2 - alkylthiazolyl, pyridyl, -CO-phenyl, -S-(C _1-2 -alkyl)-COO-(Ci _-2 -alkyl), H ₂ , N(C,. ₂ - alkyl) ₂ , -CO-C, . ₂ -alkyl. -(C _{] -2} -alkyl)-0(Ci _-2 -alkyl) and wherein, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, or in an alternative embodiment of item 9, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and wherein, when A is thi azoic, A may optionally further be substituted with a methyl group. The compound for the use according to any of the above items 1 to 9 or a physiologically functional derivative, solvate or salt thereof, wherein the X ¹ -a/.ol moiety is attached at the 5- position of the 2,3-dihydrobenzofuran mioety. The compound for the use according to above item 1 or a physiologically functional derivative, solvate or salt thereof, wherein the X ¹ -azol moiety i s attached at the 5- position of the 2,3-dihydrobenzofuran mioety;

1 is 0 or 1 ;

m is 0 or 1 ;

X ¹ is independently selected from the group comprising NR ⁿ , O or S;

R" is independently selected from the group comprising I I, methyl, ethyl, OH, - CONH ₂ , -CO H-methyl, and -COO-methyl;

R' is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, tri iluoromethyl, trifluoromethoxy, OH, methoxy, cthoxy, -CN, nitro, -NH ₂ , -N(methyl) ₂ , -NH-methyl, -NHCO-methyl, -CONH ₂ , -CONH-methyl, acetyl, -COO-methyl, and COOH;

R ² is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, triiluoromethyl. trifluoromethoxy, OH, methoxy, ethoxy, -CN. nitro, -NH2, -N(methyl) ₂ , -NH-methyl, -NHC O-methyl, -CONH ₂ . -CONH-methyl, acetyl, -COO-methyl, and -COOH; R ³ is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH ₂ , -N(methyl) ₂ . -NH-methyl, -NHCO-methyl, -CONH ₂ . -CONH-methyl, acetyl, -COO-methyl, and -COOH;

R ⁴ is independently selected from the group comprising H, Ci-3-alkyl, Ci . ₄ -haloalkyl, OH, -CONH ₂ , -CO H-C i .3-alkyl, -CO-Ci _-3 -alkyl, and -COO-d . ₃ -alkyl;

A is independently selected from the group comprising thiazole, oxazole, pyrazol c. pyrrole, benzoxazole, benzothiazole, benzimidazole. imidazole, triazole, pyrazine, triazine, pyrimidine and pyridine; or in an alternative embodiment of item 1 1 , A is independently selected from the group comprising thiazole, oxazole, pyrazol e. pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine. triazine, pyrimidine, pyridine, thiadiazole, and oxadiazole: wherein A is optionally substituted with a substituent R ^A selected from the group comprising H, CN, F, CI, Oi l, C | . ₂ -alkoxy. CF ₃ , OCF ₃ . -COOH, -COO-(C _{1 -2} -alkyl), benzyl, phenethyl, phenyl, -CO-N(C _1-2 -alkyl) ₂ , -CONH-(C _{1 -2} -alkyl), -CONH-(C| . ₂ - a]kyl}-0(C,. ₂ -alkyl), -CONH-(C _3-5 -cycloalkyl), -CONH-(C, _-2 -alkyl etrahydrofuryl), -CO-piperazinyl-(Ci _-2 -alkyl)-tetrahydrofuranyl, -CO-morholinyl, -CO-pyrrolidinyl, -CO-(methyl-piperazinyl)-. -S0 ₂ (C i _-2 -alkyl), -S-(C -alky]). -S-benzyl, -S-(c lorophenylrncthyl), and -S-phenethyl; or in an alternative embodiment of item 1 1 , A is optionally substituted with a substituent R ^A selected from the group comprising H, CN, F, CI, Br, OH, C| . ₂ -alkyl, C,. ₂ -alkoxy, CF ₃ , OCF ₃ , -COOH. -COO-(C i. ₂ -alkyl), benzyl, phenethyl, phenyl, fluorophenyl, -CO-N(C, _-2 -alkyl) ₂ , -CONH-(Ci . ₂ -alkyl), -CONH-(C , _-2 -alkyl )-0( C , _-2 - alkyl). -CONl I-(C ₃ . ₅ -cycloalkyl), -CONH-(C , . ₂ -alkyl-tetrahydrofuryl ), -CO- piperazinyl-(C 1. ₂ -alkyl )-tetrahydrofuranyl . -CO-morholinyl, -CO-pyrrolidinyl, -CO- (methyl-piperazinyl)-, -S0 ₂ (C, . ₂ -alkyl). -S-(Ci. ₄ -alkyl), -S-benzyl, -S- ( chl oropheny 1 m ethyl ) . -S-phenethyl. -CO-thienyi, -CO-pyrrolyl, -CO-piperidinyl, -CO-piperidinyl-COO-(Ci„ ₂ -alkyl), morpholinyl. Ci _-2 -alkylpiperazinyl, Ci_ ₂ - alkylthiazoiyi, pyriciyl, -CO-phenyi, -S-(Cj. ₂ -aIkyl)-COO-(C _1-2 -aikyl), NH ₂ , (C , . ₂ - alkyl) ₂ , -CO-Ci _-2 -alkyl, and -(C _1-2 -alkyl)-0(C, _-2 -alkyl); and wherein, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, or in an alternative embodiment of item 1 1 , when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and wherein, when A is thiazole, A may optionally further be substituted with a methyl group. The compound for the use according to above item 1 or a physiologically functional derivative, solvate or salt thereof, wherein the X' -azol moiety is attached at the 5- position of the 2,3-dihydrobenzofuran mioety, n is 0; m is 0; X ¹ is S, R ³ is H; R ⁴ is H;

A is a monocyclic or bicyclic hetcroaromatic ring system selected from the group comprising lH-irnidazol-2-yl, 1 //- 1 ,2,4-triazol-5-yl, 1 H-benzo [c ] i midazol -2-yl and pyridin-2-yl; or in an alternative embodiment of item 12. A is a monocyclic or bicyclic hetcroaromatic ring system selected from the group comprising l//-imidazol-2-yl, 1 //- 1.2,4-triazol-5-yl, l/J-benzo[«i]imidazol-2-yi, pyridin-2-yl, 1 ,3,4-thiadiazol-2-yl, 1 H- pyrazol-3-yl, l ,3-thiazol-2-yl, and 1 ,2,4-thiadiazol-3-yl; wherein A is optionally substituted with a substituent R ^A selected from the group comprising F, CL CN, -S0 ₂ -Me, O e. CF ₃ , -CO-N(Me) ₂ , -CO-N(Me) ₂ , 5-(4- ((tetrahydrofuran-2-yl)methyl)piperazine- 1 -carbonyl, -COO-Et, morpholine-4- carbonyl, OCF ₃ , -COO-Me, OH, -CO-NHMe, -S-Me, pyrrolidin-1 -carbonyl, -CO-NH- C ₂ H ₄ -OMe, -S-iPr, cyclopropyiearbamoyl, 4-methylpiperazine- 1 -carbonyl. -S-nPr, COOH, -S -benzyl, -S-(4-chlorobenzyl), -S-iBu, ((tetrahydrofuran-2- y 1 )m et h y 1 ) carb am o y 1 , phenethyl and -S-phencthyl; or in an alternative embodiment of item 12, A is optionally substituted with a substituent R ^A selected from the group comprising F, CI, Br. CN, methyl, -S0 ₂ -Me, OMe. CF ₃ , -CO-N(Me) ₂ , -CO-N(Me) ₂ , 5-(4-((tetrahydrofuran-2-yl)methyl)piperazine- 1 -carbonyl -COO-Et, morpholine-4-carbonyl, OCF ₃ , -COO-Me, OH, -CO-NHMe, -S- Me, pyrrolidin-1 -carbonyl, -CO-N H-C ₂ i Lj-OMe, -S-iPr, cyclopropyiearbamoyl, 4- methylpiperazine- 1 -earbonyl, -S-nPr, COOH, -S-bcnzyl, -S-(4-chlorobenzyl), -S-iBu, ((tetrahydrofuran-2-yl)methyl)carbamoyl, phenethyl, -S-phenethyl, -CO-thien-2-yl, -CO-pyrrol-2-yl, -CO-pipcridin- 1 -yl, -CQ-(4ethoxycarbonyl-piperidin-l -yl), morpholm-4-yl. 4-methyl-piperazin- 1 -yl, 5 -methyl -thi azo 1 -2 -y 1. pyridin-4-y1, -CO- phenyl -S-(CH ₂ )-COO e, NH ₂ , -CO-Ci _-2 -alkyl. 3 -fluorophenyl, acetyl, -methylthio, and m ethoxym ethyl ; and wherein, when A is l //-benzo[r/|inndazol-2-yl, A may optionally further be substituted with a chlorine atom, or in an alternative embodiment of item 12, when A is 1 // -benzol c/j i midazo 1-2-yl, A may optionally further be substituted with a chlorine atom, and when A is 1.3-thiazol-

2-yl, A may optionally further be substituted with a methyl group.

The compound for the use according to above item 1 or a physiologically functional derivative, solvate or salt thereof, wherein said compound is selected from the group comprising the compounds 1 to 47, or in an alternative embodiment of item 13 compounds 1 to 82, as shown below in the Table 1 .

Table 1 : Specific compounds of the present invention (the production thereof is described in

WO 2014/202638 Al :

In certain embodiments, n is an integer from 0 to 1. more particularly n is 0.

In certain embodiments, m is an integer from 0 to 2, more particularly 0 to 1 , even more particularly 0.

In certain embodiments, p is an integer from 0 to 3, more particularly 0 to 2, even more particularly 0 to 1 , yet even more particularly 1 ,

In certain embodiments, R ¹ is independently selected from the group comprising H, halogen, Ci-4-aIkyl, benzyl, C _{\ 4} -haloalkyl, Ci-4-haloalkoxy, OH, C ₁ .4-alko.xy, -CN, phenyl, naphthyl, pyridyl, pyrrolyl, furanyl, tliienyl, thiazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohcxyl, cycloheptyl. decalinyl, tetrahydrofuryl, tetrahydropyranyl. tetrahydrothienyl, piperidyl, piperazinyl, morpholinyl, pyrrolidinyl,

-S-C,_ ₄ alkyl, -SO-C _{] -4} alkyl, nitro, -NH ₂ , -N(C _1-4 alkyl) ₂ , -NH-C, . ₄ alkyl. -NHCO-C _{1 -4} alkyl, -CONH2, -CONH-C, _-4 alkyl, -CO-C alkyl, -COH. -COO-C _{l -4} alkyl.

-COOH, -SO ₂ NH ₂ , -S0 ₂ NH-Ci _-4 alkyl, -S0 ₂ -C ₁ . ₄ alkyl -NH-S0 ₂ -C _{1 -4} alkyl and -NHCOC-CV

₄ alkyl.

In more particular embodiments, R ^l is independently selected from the group comprising H, halogen, C^-alky!, benzyl, Ci _-4 -haloalkyl, C i -4-haloalkoxy, OH, Ci-4-alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl. cyclopentyl, cyclohexyl, -S-C i. ₄ alkyl, -SO-C _i-4 alkyl. nitro, - H ₂ , -N(Ci_ ₄ alkyl) ₂₅ -NH-C ,_ ₄ alkyl, -NHCO-C i ₄ alkyl, -CONH ₂ , -CONH-Ci ^aikyl, -CO-C, ₄ alkyl, -COO-C i _-4 alkyl. -COOH. -S0 ₂ NH ₂ , -S0 ₂ NH-C _M alkyL -S0 ₂ -C _{l -4} alkyl, -NH-S0 ₂ -C ,. ₄ alkyl and -NHCOO-Ci _-4 alkyl.

In even more particular embodiments, R ¹ is independently selected from the group comprising H, halogen, C| . ₄ -alkyl, C| . ₄ -haloalkyl. CVi-haloalkoxy, OH, C i_ ₄ -alkoxy, -CN, cyclopropyl, cyclobutyl, nitro, -NH ₂ , -N(C _{] -4} alkyl) ₂ , -NH-C _1-4 alkyl, -NHCO-Ci- alkyl, - CONH2,

-CONH-C| . ₄ alkyl, -CO-C, _-4 alkyl, -COO-C,. ₄ alkyl, and -COOH.

In yet even more particular embodiments, R ¹ is independently selected from the group comprising H, halogen, Ci _-4 -alkyl, Ci _-4 -haloalkyl, d-4-haloalkoxy, OH, C | 4-alkoxy, -CN, nitro. -NH ₂ , -N(Ci _-2 alkyl) ₂ , -NH-CV ₂ a]kyl, -NHCO-C^alkyl, -CONH ₂ , -CONH-C _1-2 alkyl, -CO-C,. ₂ alkyl, ~COO-C, _-2 aikyl, and -COOH.

In yet even more particular embodiments, R ¹ is independently selected from the group comprising 11, fluorine, chlorine, bromine, trifluoromethyl, difluoromethyl, trifluoromethoxy, OH, Ci. ₃ -alkoxy. -CN, nitro, -NH ₂ , -N(C, . ₂ alkyl) ₂ . -NH-C,. ₂ alkyl, -NHCO-Ci ₂ alkyl, -CONH ₂ , -CONH-Ci ₂ alkyl, -CO-C,_ ₂ alkyl, -COO-C _{1 2} alkyl and -COOH. In yet even more particular embodiments, P. ¹ is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN. nitro, -NH ₂ . -N(methyl) ₂ , -NH-methyl, -NHCO-methyl, -CONH ₂ . -CONH-methyl, acetyl, -COO-methyl, and -COOH.

In yet even more particular embodiments, R ^! is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.

In yet even more particular embodiments, R ¹ is independently selected from the group comprising H, fluorine, chlorine, metliyl, trifluoromethyl. trifluoromethoxy, OH, and methoxy.

Most particularly, R ^l is independently H.

In certain embodiments, R ² is independently selected from the group comprising H, halogen, Ci-4-alkyl, benzyl, Q-4-haloalkyl, Ci _-4 -haloalkoxy, OH, Ci _-4 -alkoxy, -CN. phenyl, naphthyl, pyridyl, pyrrol yl. furanyl, thienyl, thiazolyl, oxa/olyl. pyrazolyl, cyclopropyl, cyclobutyl. cyclopentyl, cyclohexyl, cycl heptyl, decalinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothienyl, piperidyl, piperazinyL morpholinyl, pyrrolidinyl, -SO-C,. ₄ alkyl, nitro, -NH ₂ . -N(Ci. ₄ alkyl) ₂ , -NH-C _1-4 alkyl, -NHCO-Ci. ₄ alkyl, -CONH2, -CONH-C|_ ₄ alkyl, -CO-C| _-4 alkyl, -COH. -COO-C alkyl, -COOH, -S0 ₂ NH ₂ , -S0 ₂ NH-C alkyl, -S0 ₂ -C _1-4 alkyl, -NH-S0 ₂ -Ci. ₄ alkyl and -NHCOO-C _{! -4} alkyl.

In more specific embodiments, R ² is independently selected from the group comprising H, halogen, C _1-4 -alkyl, benzyl, C _{! -4} -haloalkyl, Cj. ₄ -haloalkoxy, OH, C _)-4 -alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -S-Ci_ ₄ alkyl, -SO-Ci. alkyl, nitro, -NH ₂ , -N(C _1-4 alkyl) ₂ , -NH-C, _-4 alkyl, -NHCO-C^alkyl, -CONH ₂ , -CONIi-C alkyl, -CO-Ci _-4 alkyl, -COO-C | . alkyl, -COOH. -S0 ₂ NH ₂ , -S0 ₂ NH-C| . ₄ alkyl, -S0 ₂ -Ci. ₄ alkyl, -NH-S0 ₂ -C , _-4 alkyl and -NHCOO-C _{i -4} alkyl. In even more particular embodiments, R ² is independently selected from the group comprising H, halogen, d . -alkyl, C _{] -4} -haloalkyl, Ci . ₄ -haloalkoxy, OI L C |. ₄ -alkoxy, -CN, cyelopropy], cyelobutyl, nitro, -NH ₂ , -N(C alkyl) ₂ , -NH-C, _-4 alkyl, -NHCQ-Ci . ₄ alkyl. -

CONH ₂ ,

-CONH-C | . ₄ alkyl, -CO-C alkyl, -COO-C _{1 -4} alkyl and -COOH.

In yet even more particular embodiments, R ² is independently selected from the group comprising H, halogen, Ci _-4 -alkyl, C| _-4 -haloalkyl, C i _-4 -haloalkoxy, OH, Ci _-4 -alkoxy, -CN, nitro, -NH ₂ , -N(C _{l -2} alkyl) ₂ , -NH-C,. ₂ alkyl. -NHCO-C, . ₂ alkyl, -CO H ₂ , -CONH-C _1-2 alkyl, -CO-Ci _-2 alkyl, -COO-C, _-2 alkyL and -COOH.

In yet even more particular embodiments, R ² is independently selected from the group comprising H, fluorine, chlorine, bromine, Chalky!, trifluoromethyl, dilluoromethyl, trifluoromethoxy, OH, C _1-3 -alkoxy, -CN, nitro, -NH ₂ , -N(C _{] -2} alkyl) ₂ , -NH-C, _-2 alkyl. -NHCO-C| . ₂ alkyl, -CONH ₂ , -CONH-C|. ₂ alkyl -CO-C,. ₂ alkyl, -COO-C _{1 -2} alkyl. and -COOH.

In yet even more particular embodiments, R ² is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, Oi l. methoxy, ethoxy, -CN, nitro, -NH ₂ , -N(methyl) ₂ , -NH-methyl. -NHCO-methyl, -CONH ₂ , -CONH-methyl, acetyl, -COO-methyl, and -COOH.

In yet even more particular embodiments, R ² is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy. In yet even more particular embodiments, R ² is independently selected from the group comprising H, fluorine, chlorine, methyl, trifluoromcthyl, tri fl uorom ethox y, OH, and methoxy.

Most particularly, R is independently 11. In certain embodiments, R ³ is independently selected from the group comprising H, halogen, Ci-4-alkyl, benzyl, C i _-4 -haloalkyl, Ci_4-haloalkoxy, OH, C _{i -} -alkoxy, -CN, phenyl, naphthyl, pyridyl, pyrro!yl, furanyl, thienyl, thiazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, eyclopentyl, cyclohexyl, cycloheptyl. dccalinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydro thienyl, piperidyi, piperazinyl, morpholinyl, pyrrolidinyl, ~S-C,_ ₄ alkyL -SO-C alkyl, nitro, -NH ₂ . -N(C _1-4 alkyl) ₂ , -NH-C _1-4 alkyl, -NHCO-C _{! -4} alkyl. -CONH ₂ . -CONH-C _{1 -4} a!ky!, -CO-C;. ₄ alkyL -COH, -COO-C _{! -4} a!kyl. -COOH, -S0 ₂ N¾, -S0 ₂ NH-C,. ₄ alkyl, -S0 ₂ -C _M aIkyl, -NH-S0 ₂ -Ci . ₄ alkyl and -NHCOO-C _{1 -4} alkyl.

In more particular embodiments, R ³ is independently selected from the group comprising H, halogen, C _{] -4} -alkyl ₅ benzyl, d-4-haloalkyl, Ci _-4 -haloalkoxy, OH, Q _-4 -alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl, eyclopentyl, cyclohexyl. -S-Cj . ₄ alkyl, -SO-C _{1 -4} alkyl, nitro. -NH ₂ , -N(Ci ₄ alkyl} ₂ , -NH-C _{1 -4} alkyl, -NHCO-Ci _-4 alkyl, -CONH ₂ , -CONH-C, . ₄ alkyl, -CO-C, . ₄ alkyl. -COO-C,. ₄ alkyl, -COOH, -S0 ₂ NH ₂ , -S0 ₂ NH-C,. ₄ alkyl, -S0 ₂ -C _{1 -4} alkyl. -NH-S0 ₂ -C _1-4 alkyl and -NHCOO-C, _-4 alkyl.

In even more particular embodiments, R ³ is independently selected from the group comprising H, halogen, Ci _-4 -alkyl, ₄ -haloalkoxy, OH. C| ₄ -alkoxy. -CN, cyclopropyl, cyclobutyl, nitro, -N -NH-C,. ₄ alkyl, -NHCO-Ci _-4 alkyl, - CONH ₂ , -CONH-C, _-4 alkyl. -CO-C, _-4 alkyl, -COO-C,. ₄ alkyl, and -COOH.

In yet even more particular embodiments, R ³ is independently selected from the group comprising H, halogen, C ]. -alkyl, C]. ₄ -haloalkyl, Ci _-4 -haloalkoxy, OH, C | . -alkoxy, -CN, nitro, -NH ₂ , -N(C _{l -2} alkyl) ₂ , -NH-C| . ₂ alkyl, -NHCO-C,. ₂ alkyl, -CONH ₂ . -CONH-C _{] -2} alkyl, -CO-C i . ₂ alkyl, -COO-C _{1 -2} alkyl, and -COOH.

In yet even more particular embodiments, R ³ is independently selected from the group comprising H, fluorine, chlorine, bromine, Ci.?alkyl. trifluoromethyl, difluoromethyl. trifluoromethoxy, OH. Ci. _? -alkoxy, -CN. nitro, -NH ₂ , -N(C| . ₂ alkyl) ₂ , -NH-C, _-2 alkyl, -NHCO-Ci. ₂ alkyl, -CONH ₂ , -CONH-C, ₂ alkyl. -CO-C). ₂ alkyl, -COO-C,. ₂ alkyl, and -COOH.

In yet even more particular embodiments, R ³ Is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl. trifluoromethyl. trifluoromethoxy, OH, methoxy, etlioxy, -CN, nitro. -NH ₂ , -N ( methyl):. -NH-methyl. -NHCO-methyl, -CONH ₂ , -CONH-methyl, acetyl, -COO-methyl, and -COOH.

In yet even more particular embodiments, R ³ is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.

In yet even more particular embodiments, P. ³ is independently selected from the group comprising H, fluorine, chlorine, methyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.

Most particularly, R ³ is independently H.

In certain embodiments, R ⁴ is independently selected from the group comprising H, Ci-4-alkyl, benzyl, OH, C | .4-alkoxy, phenyl, naphthyl, pyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyrazolyl. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, decalinyl, tetrahydrofuryl. tetrahydropyranyl, tetraliydrothicnyl. piperidyl, piperazinyl, mo holinyl, pyrrolidinyl, -CONH ₂ , -CONH-C , .4-alkyl. -CO-C, _-4 -alkyl, -COO-C _{! -4} -alkyl, and -S0 ₂ -C _{! -4} -alkyl.

In more particular embodiments, R ⁴ is independently selected from the group comprising H, C| -alkyL benzyl, Ci- -haloalkyb Ci 4-haloalkoxy, OH, C| ₄ -alkoxy, phenyl, -CONH ₂ , -CONH-C | _-4 -alkyl, -CO-C, _-4 -alkyl, -COO-C, .,-alkyh and -S0 ₂ -C, .4-alkyl. In more particular embodiments, R ⁴ is independently selected from the group comprising H, Ci _-3 -alkyl, C _{1 -4} -haloalkyl, OH, -CONH ₂ , -CONH-C _{i -3} -alkyl, -C -C|_j-alkyl, and

-COO-C, .3-alkyl.

In even more particular embodiments. R ⁴ is independently selected from the group comprising H, methyl, ethyl, OH. -CONH ₂ , -CONH-mcthyl, and -COO-methyl.

In yet even more particular embodiments, R ⁴ is independently selected from the group comprising H, and methyl. Most particularly, R ⁴ is independently H.

In certain embodiments, X ¹ is O or S. In more specific embodiments, X ¹ is S, In certain embodiments, R" is independently selected from the group comprising H, Ci-4-alkyl, benzyl, Q-4-haloalkyl, Ci _-4 -haloalkoxy, OH, Cj _-4 -alkoxy, phenyl, naphthyl, pyridyl, pyrrolyl, furanyl, thienyl, thlazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, cyc!opcntyl, cyclohexyl, cyc!ohcptyl, decalinyl, tetrahydrofuryl, tetrahydropyrany! , tetrahydrothienyi, piperidyi piperazinyl, morpholinyl, pyrrolidinyl, -CON¾, -CONH-C _{1 4} -alkyl. -CO-C _1-4 -alkyl, -COO-C|. ₄ -alkyl, and -S0 ₂ -Ci ₄ -alkyl.

In more particular embodiments, R ⁿ is independently selected from the group comprising H, C] _4-alkyl, benzyl, C _1-4 -haloalkyl, C _)-4 -haloalkoxy, OH, C _1-4 -alkoxy, phenyl, -CONH ₂ , -CONH-C -alkyl, -CO-C -alkyl, -COO-C,. ₄ -alkyl, and -S0 ₂ -C _{l -4} -alkyl.

In more particular embodiments, R ⁿ is independently selected from the group comprising H, Ci. ₃ -alkyl, C -haloalkyl, OH, -CON¾, -CONH-C|. _? -alkyl, -CO-Cj. ₃ -alkyl, and -COO-Cralkyl. In even more particular embodiments, R" is independently selected from the group comprising II, methyl, ethyl, OH, -CONH ₂ , -CO H-methyl, and -COO-methyl.

In yet even more particular embodiments, R" is independently selected from the group comprising 11, and methyl. Most particularly, R" is independently H.

In certain embodiments, A is a monocyclic or bicyclic heteroaromatic ring system consisting of 5 to 9 ring atoms, at least one of which is an N atom, wherein optionally one or two further ring atoms are heteroatoms independently selected from the group comprising O, S and N, particularly , and wherein the remaining ring atoms are carbon atoms.

In more particular embodiments, A is a monocyclic heteroaromatic ring system consisting of

5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms arc heteroatoms independently selected from the group comprising O, S and N and wherein the remaining ring atoms are carbon atoms.

In other more particular embodiments, A is a 5-membered monocyclic heteroaromatic ring which is optionally fused to a phenyl ring, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms.

In other more particular embodiments, A is a 5-membered monocyclic heteroaromatic ring which is optionally fused to a phenyl ring, wherein at least one of the ring atoms is an N atom, wherein optionally one further ring atom is an N atom and/or one further ring atom is an O or

S atom, and wherein the remaining ring atoms are carbon atoms.

In even more particular embodiments, A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bi cyclic heteroaromatic ring system consisting f 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms.

In other even more particular embodiments, A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N ato s,

or one further ring atom is an O or S atom,

or one further ring atom is an N atom and one ring atom is an O or S atom,

and wherein the remaining ring atoms are carbon atoms

In other more particular embodiments, A is independently selected from the group comprising thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine. triazinc, pyrimidinc and pyridine, even more particularly thiazol-2-yl, oxazol-2-yl, pyrazol-2-yl, pyrrol-2-yl, bcnzoxazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl. imidazol-2-yl, triazol-5-yl. pyrazin-2-yl. triazin-2-yl, pyrimidin-2-yl and pyridin-2-yl.

In other more particular embodiments, A is independently selected from the group comprising thiazole, oxazole. pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine. triazinc, pyrimidine, thiadiazole, oxadiazole, and pyridine, even more particularly thiazoi-2-yl, oxazol-2-yl, pyrazol-2-yl. pyrrol-2-yl, benzoxazol-2-yl, ben/.othi a/.ol -2-yl , ben/.imidazol-2-yl, imidazol-2-yl, triazol-5-yl. pyrazin-2-yl, triazin-2-y , pyrimidin-2-yl, thiadiazol-2-yl, thiadiazol-3-yl, thiadiazol-5-yl, oxadiazol-2-yi, oxadiazol-3- yl, oxadiazol-5-yl, and pyridin-2-yL

In yet even more particular embodiments, A is independently selected from the group comprising imidazolyl, triazolyl, benzoimidazol and pyridinyl, In other yet even more particular embodiments, A is independently selected from the group comprising imidazolyl, triazolyl, bcnzoimidazolyl. benzothiazolyl, thiadiazolyl, pyrazolyl, thiazolyl, oxazolyh oxadiazolyl and pyridinyl.

In yet even more particular embodiments, A is independently selected from the group comprising l//-imidazol-2-yL 1 //- 1 ,2,4-triazol-5-yI, l / -benzofi ]imidazol-2-yl and pyridin-2- yi

In other yet even more particular embodiments, A is independently selected from the group comprising lH-imidazol-2-yl, 1 //- 1 ,2,4-triazol-5-yl. l //-benzo[i/jimidazol-2-yl, pyridin-2-yl, l ,3.4-thiadiazol-2-yl, lH-pyrazol-3-yi, l ,3-thiazol-2-yh l ,2,4-thiadiazol-3-yl. 1 ,3,4- thiadiazol-2-yl, J .2,4-thiadiazol-5-yl. l ,3-oxazol-2-yl and l ,2,4-oxadia/.ol-3-yl.

In yet even more particular embodiments, A is independently selected from the group comprising benzimidazol-2-yl and imidazol-2-yl.

In other yet: even more particular embodiments, A is independently selected from the group comprising benzimidazol-2-yl, imidazol-2-y], 1 ,3,4-thiadiazol-2-y!, lH-pyrazol-3-yl, 1 ,3- thiazol-2-yl, and 1 ,2,4-thiadiazol-3-yl. Most particularly, A is independently benzimidazol-2-yl.

In other embodiments, most particularly, A is independently independently selected from the group comprising benzimidazol-2-yl, 1 ,3.4-thiadiazol-2-yl, lH-pyrazol-3-yl, and 1 ,3-thiazol-

2-yl. In all embodiments described herein, A may be substituted, where appropriate and chemically feasible, with 0 to 4, particularly, 0 to 2, more particularly 0 to 2, even more particularly 1 or 2 substituents R ^A , wherein R ^A is independently selected as detailed in the embodiments as described herein. In certain particular embodiments, the thiazole, oxazole, pyrazole, pyrrole, or imidazole group A is particularly optionally substituted with one R ^A substituent in position 4, the triazole group A is optionally substituted with R ^A in position 3, the pyrazine. triazine, pyri idine or pyridine group A is optionally substituted with R ^A in position 5, and the benzoxazole, benzothiazole, or benzimidazole group A is optionally substituted with R ^A in position 5 and/or 6, even more particularly optionally substituted with R ^A in position 5 and further optionally substituted in position 6 with a group selected from the group comprising halogen, methyl, ethyl, CF ₃ , CN, N0 ₂ , COOH, OH, NH ₂ , NMe ₂ , and COOMe, more particularly selected from the group comprising halogen, methyl, CF ₃ , CN, and OH, even more particularly selected from the group comprising fluorine, chlorine, bromine, CF ₃ , CN and OH, yet even more particularly selected from the group comprising fluorine and chlorine, most particularly chlorine.

In other certain particular embodiments, the thiazole, oxazole, pyrazole, pyrrole, or imidazole group A is particularly optionally substituted with one R ^A substituent in position 4 or 5, the triazole group A is optionally substituted with R ^A in position 3, the pyrazine, triazine, pyrimidine or pyridine group A is optionally substituted with R ^A in position 5, and the benzoxazole, benzothiazole, or benzimidazole group A is optionally substituted with R ^A in position 5 and/or 6, or alternatively in position 1 , and further optionally substituted in position 5 or 6 (whichever one is available) with a group selected from the group comprising halogen, methyl, ethyl, CF ₃ , CN, N0 ₂ , COOH, OH, NH ₂ , NMe ₂ , and COOMe, more particularly selected from the group comprising halogen, methyl, CF ₃ , CN, and OH, even more particularly selected from the group comprising fluorine, chlorine, bromine, CF ₃ , CN and OH, yet even more particularly selected from the group comprising fluorine and chlorine, most particularly chlorine. For sake of completeness, it is mentioned that thiadiazolc and oxadiazole groups are optionally substituted at the ring carbon atom available for binding.

In other more particular embodiments, A is a group of formula (la) (la), wherein

X ² is a group selected from the group comprising N and ethenylene, which may optionally be substituted by one or two R ^A : X ³ is an atom selected from the group comprising C and N which may optionally be substituted by R ^A ; R ⁵ is a substituent group selected from the groups as defined herein for R ^A , or R ⁵ , together with X ³ forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R ^' \

In other more particular embodiments, A is an aromatic group of formula (la)

(la), wherein

X ² is selected from the group comprising N, S, O, NH, CI I, CR ^A and ethenylene optionally substituted by one or two R ^" \ particularly selected from the group comprising N, S, O, NH, CH and CR ^A ; X ³ is selected from the group comprising N, S, NH, CH and CR ^A ; X ⁶ is selected from the group comprising N, S, O, NH, CH and CR ⁵ , wherein R ⁵ is a substituent group selected from the groups as defined herein for R , or R , together with X ^' ' forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R ^A , particularly in positon 5 or 6 of a resulting benzazole derivative, wherein particularly said group A comprises not more than one atom selected from O and S and not more than three heteroatoms in total. other more particular embodiments, A is a group of formula (lb)

wherein

X ⁴ is selected from the group comprising CH and NH; X ⁴ is selected from the group comprising CH and a single bond; X ³ is an atom selected from the group comprising C and N which may optionally be substituted by R ^A ; R ⁵ is a substitucnt group selected from the groups as defined herein for R '\ or R\ together with X ³ forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by more R ^A .

In et other more particular embodiments, A is an aromatic group of formula (la)

((a), wherein

X ⁴ is selected from the group comprising N, S, O. NH. CH and CR ^A ; X ⁵ is selected from the group comprising CH and a single bond, particularly a single bond: X ³ is selected from the group comprising N. S, NH, CH and CR ^A ; X ⁶ is selected from the group comprising N, S, O,

NH, CH and CR ⁵ , wherein R ⁵ is a substituent group selected from the groups as defined herein for R ^' \ or R , together with X ³ forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R ^A , particularly in positon 5 or 6 of a resulting benzazole derivative, wherein particularly said group A comprises not more than one atom selected from O and S and not more than three heteroatoms in total.

For explanation, when R ⁵ , together with X ³ forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R ^A , particularly in positon 5 or 6 of a resulting benzazole derivative, said positon 5 or 6 of a resulting benzazole derivative is as shown in the below structure:

In certain embodiments, R ^A is independently selected from the group comprising H, CN, NO:, halogen OH, alkoxy, haloalkyl. alky], haloalkoxy, -COOH, -COO-alkyl, aralkyl, aryl, -CO-N(alkyl) ₂ , -CONH-(alkyl), -CONH-alkyl-alkoxy. -CO H-cycloalkyl, -CONH-alkyl- heterocycloalkyl, -NHCO-(alkyl), - NHCO-alkyl-alkoxy. - NHCO-cycloalkyl. - NHCO-alkyl- hctcrocycloalkyl. -CO-hcterocycloalkyl-alkyl-heterocycloalkyl, -CO-heterocycloalkyl. -S0 ₂ - alkyl. -S-alkyL -S-aralkyl, -CO-heteroaryl, heteroaryl. -heterocycloalkyl-alkoxycarbonyl. - CO-aryl, -S-alkyl-COO-alkyl, halophenyl, NH ₂ , NH(alkyl), N(alkyl), -CO-alkyl. and -alkyl- O-alkyL

In certain embodiments, R ^A is independently selected from the group comprising H, CN, N0 ₂ , halogen OH, alkoxy, haloalkyl. alkyl, haloalkoxy. -COOH, -COO-alkyl. aralkyl. aryl, -CO-N(alkyl) ₂ , -CON H -(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl. -CO H-alkyl- heterocycloalkyl, -NHCO-(alkyl), - NHCO-alkyl-alkoxy, - NHCO-cycloalkyl. - NHCO-alkyl- heterocycloalky!, -CO-heterocycloalkyl-alkyi-heterocycloalkyl, -CO-heterocycloalkyl, -S0 ₂ ~ alkyl, -S-alkyl, and -S-aralkyl.

In further embodiments, R ^A is independently selected from the group comprising H, CN, N0 ₂ , halogen OH, alkoxy, haloalkyl. alkyl, haloalkoxy, -COOH. -COO-alkyl. aralkyl. aryl, -CO- N(alkyl) ₂ , -CONH-(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl, -CONH-alky!- heterocycloalkyl, -CQ-heterocycloalkyl-alkyl-heteroeycloalkyl, -CO-heterocycloalkyl, -S0 ₂ -alkyl, -S-alkyl, and -S-aralkyl.

In more particular embodiments, R ^A is independently selected from the group comprising H. CN, N0 ₂ , halogen, OH, alkoxy, haloalkyl, alkyl, haloalkoxy. -COOH. -COO-alkyl, aralkyl, aryl. -CO-N(alkyl) ₂ , -CONH-(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl. -CONII- a lk yl -hct erocycl o al kyl . -CO-hctcrocycloalkyl-alkyl-heterocycloalkyl, -CO-heterocycloalkyl.

-S0 ₂ -alkyl, -S-alkyl, -S-aralkyl, -CO-heteroaryl, heteroaryl. -heterocycloalkyl- alkoxycarbonyl, -CO-aryl, -S-alkyl-COO-alkyl, halophenyl, N¾ NH(alkyl), N(alkyl), -CO- alkyl, and -alkyl-O-alkyl.

In more particular embodiments, R ^A is independently selected from the group comprising H, CN. N0 ₂ . halogen OH, alkoxy, haloalkyl, alkyl, haloalkoxy, -COOH. -COO-alkyl. aralkyl, aryl -CO-N(alkyl) ₂ , -CONH-(alkyl). -CONH-alkyl-alkoxy, -CONH-cycloalkyl, -CONH- alkyl-heterocycloalkyl, -CO-heterocycloalkyl-alkyl-heterocycloalkyl, -CO-heterocycloalkyl, -S0 ₂ -alkyl, -S-alkyl. and -S-aralkyl.

In even more particular embodiments. R ^A is independently selected from the group comprising H, CN, halogen, OH, Ci _-4 -alkoxy, Ci^-alkyl, Ci _-4 -haloalkyl, Ci_ ₄ -haloalkoxy, - COOH, -COO-(Ci. ₄ -aikyl), ben/yl, phenethyl. phenyl. -CO-N(C, _-3 -alkyl) ₂ . -CON H -(C _h alky!), -CONH -(C i -a!kyl )-0( C , ₃ -alkyl), -CONH-(C ₃ - ₅ -cycloalkyl), -CONH-(C ralkyl)-(CV 6-heterocycloaikyl), -CO-(C _5- 6-heterocycloalkyl)-(Ci.3-alkyl)-(C5 _-6 -heterocycloalkyl), -CO- (C _5- 6-heterocycloalkyl), -S0 ₂ (Ci. ₄ -alkyl), -S-(C -alkyl), -S-benzyl, -S-(chlorophenylmethyl), -S-phenethyl, -CO-(C _5- 6-heteroaryl), C _5-6 -heteroaryl, -C _5-6 -heterocycloalkyI-(C _1-4 - alkoxycarbonyl), -CO-phenyl, -S-(C , _-4 -alkyl )-COO-(C , alkyl), halophenyl, NH ₂ , NH(C - alkyl), N(C, _-4 -alkyl) ₂ , -CO-(C -a1ky1), and -(C , _ -alkyl)-0-(C , _-4 -alkyl).

In even more particular embodiments, R ^A is independently selected from the group comprising H, CN, halogen OH, C _; _4-alkoxy, Ci-4-alkyl, Ci. ₄ -haloalkyl, C ;„ -haloaIkoxy, - COOH, -COO-(C _M -alkyl), benzyl, phenethyl, phenyl, -CO- (C ₁ . ₃ -alkyl) ₂ , -CO H-(C _{! -} alkyl), -CONH-(C,. ₃ -alkyl)-0(C,. ₃ -alkyl), -CONH-(C ₃ . ₅ -cycloalkyl), -CONH-(Ci .ralkyl)-(C5- 6-hctcrocycloalkyl ), -CO-(C ₅ -6-heterocycloalkyl)-(Ci-3-alkyl)-(C _5- 6-heterocycloalkyl), -CO- (C ₅ . ₆ -heterocycloalkyl), -S0 ₂ (C _{1 -4} -alkyl), -S-(C _1-4 -alkyl), -S-benzyl, -S-(chlorophenylniethyl), and -S-phenethyl,

In yet even more particular embodiments, R ^A is independently selected from the group comprising H, CN, F, CI, OH, C _1-2 -alkoxy, CF ₃ , OCF ₃ , -COOH, -COO-(Ci- ₂ -alkyl), benzyl, phenethyl, phenyl, -CO-N(C _{i 2} -alkyl) ₂ , -CONH-(C _{1 -2} -alkyl), -CONH-(Ci _-2 -alkyl)-0(Ci _-2 - alkyl), -CONH-(C ₃ - ₅ -cycloalkyl), -CONH-(C,. ₂ -alkyl4etrahydrofuryl), -CO-piperazinyl-id ₂ - alkyl)-tctrahydrofuranyl, -CO-morholinyl, -CO-pyrrolidinyl, -CO-(methyl-piperazinyl)-, -S0 ₂ (Ci-2-alkyl). -S-(C _M - alkyl), -S-benzyl, -S-(chiorophenylmethyl). -S-phenethyl, -CO- thien-2-yl, -CO-pyrrol-2-yl, -CO-morphol in-4-yl , piperidin- l -yl-, 4-(C 1. ₂ -alkoxycarbonyl)- piperidin-l -yl, C] ₂ -alky1, C ^-alkoxycarbonyl, moi holin-4-yl, 4-pyridyl, -CO-phenyl, -S- (Ci_2-alkyl)-COO-(Ci _-2 -alkyl), Br, 3 -fluorophenyl, NH ₂ , -CO-(C _1-2 -alkyl), -S-(C _{i -2} -alkyl), and -(C| _-2 -alkyl)-0-(C, _-2 -a]kyl).

In yet even more particular embodiments, R ^A is independently selected from the group comprising H, CN, F, CI, OH, C, ₂ -alkoxy, CF ₃ , OCF ₃ , -COOH, -COO-(C ,. ₂ -alkyl), benzyl, phenethyl, phenyl -CO-N(C _{1 2} -alkyl ) ₂ , -CONH-(C, _-2 -alkyl), -CONH-(C _1-2 -alkyl)-0(Ci_ ₂ - alkyi), -CONH-(C _3-5 -cycloalkyl), -CO-piperazinyl-(C _1-2 - alkyl)-tetrahydrofuranyl, -CO-morholinyl, -CO-pyrrolidinyl, -CO-(methyl-piperazinyl)-, -S0 ₂ (Ci. ₂ -alkyl). -S-(Ci. ₄ -alkyl), -S-benzyl. -S-(chlorophenylmethyl), and -S-phenethyl.

In yet even more particular embodiments, R ⁿ is independently selected from the group comprising I I, CN, F, CI, -S0 ₂ Me, -OMe, CF ₃ , -CO-NMe ₂ , -CO-piperazine- 1 ,4-yl-CH ₂ - tetrahydrofurane-2-yl, -COO-Et, -CO-morholinc- l -yl, 3-iiietlioxyphenyl, OCF ₃ , -COOMe, OH, -CONH-Me, -SMe, -CO-pwolidine-l -yl, -CONH-CH _: -CH ₂ -OMe, -S-iPr, -CONH- cyclopropyl, -CO-(4-methyl-piperazine- 1 -yi )-, -S-nPr, -COOH, -S-benzyl, -S-(4- chloroplienylmethyl), -S-iBu. -CONH-CH ₂ -tetrahydroiuranc-2-yl, phenethyl, -S-phenethyl, - CO-thien-2-yl, -CO-pyrrol-2-yl, -CO-morpholin-4-yl, piperidin- l -yl-, 4-ethoxycarbonyi - piperidin- l -yl, methyl, ethoxycarbonyl, morpholin-4-yl. 4-pyridyl, -CO-phenyl, -S~CH ₂ ~ COO-Et, Br. 3 -fluorophenyl, NH ₂ , acetyl, -S-Me, and -Clb-OMe.

In yet even more particular embodiments, R ^A is independently selected from the group comprising H, CN, F, CI, -S0 ₂ Me, -OMe, CF ₃ , -CO-NMe ₂ , -CO-piperazine- 1 ,4-yl-CH ₂ - tetrahydrofurane-2-yl, -COO-Et, -CO-morholine- l -yl. 3-methoxyphcnyl, OCF ₃ , -COOMe, OH. -CONH-Me. -SMe, -CO-pyrroiidine- l -yl, -CQNH-CH ₂ -CH ₂ -OMe, -S-iPr, -CONH- cyclopropyl, -CO-(4-methyl-piperazine- 1 -yl)-, -S-nPr, -COOH, -S-benzyl, -S-(4- chlorophenylmethyl), -S-iBu, -CONH-CH ₂ -tetrahydrofarane-2-yl, phenethyl, and -S-phenethyl.

In other particular embodiments, R ^A is independently selected from the group comprising H, - S0 ₂ (C _M -alkyl), -CO-N(C -alkyl) _? , -CO-NH(C i _-4 -alkyl), -CO-NH ₂ , -CO-fC _{5 6} - heterocycloalkyl)-Ci _-4 -alkyl-(C ₅ . ₆ -heterocycloalkyl), -COO-(C i _-4 -alkyl). -CO-(C ₅ . ₆ - hetcrocycloalkyl). -CONH-C , _-4 -alkyl-0(C , _-4 -aikyl ), -CONH-C i _-4 -alkyl -(C ₅ . ₆ -heteroaryl ), halogen, C,. ₄ -haloalkyl, 3-(C, ₄ -alkoxy)-aryl C -haloalkoxy, -CONH-(C _M -alkyl). -CONH-

(C3_5-cycloalkyl), -(C _5- 6-heterocycloalkyl)-(Ci-4-alkyl), C ₅ - ₆ -heteroaryl, and -CO-(Ci.4-alkyi)- ( C j _-6 -heterocycl oal k y! ), -CO-(C ₅ .6-heteroaryl), -CO-(C _5-6 -heterocycloalkyl), -(C _5- 6- heterocycloalkyl)-(Ci _-4 -alkoxycarbonyl), Ci _-4 -alkyl, C _{] -4} -alkoxycarbonyl, -CO-phenyl, -S-(C | ₄ -alkylene)-COO-(Ci . ₄ -alkyl). and C _{! -4} -alkoxy.

In other particular embodiments, R ^A is independently selected from the group comprising H, - S0 ₂ (Ci . ₄ -alkyl). -CO-N(C , ₄ -alkyl) ₂ , -CO-NH(C _1-4 -alkyl), -CO-NH ₂ , -CO-(C _5-6 - heterocycloalkyl)-C] - -alky]-(C . ₆ -heteroeycloalkyl), -CQO-(C -alkyl). -CO-(C _5-6 - heterocycloalkyl), -CONH-C, . ₄ -alkyl-0(C, . ₄ -alkyl), -CONH-Ci _-4 -alkyl-(C ₅ - ₆ -heteroaryl), halogen, C _{1 -4} -haloalkyl, 3-(C -alkoxy)-aryl, C _1-4 -haloalkoxy, -CO H-(C -alkyl), -CONH- (Cv ₅ -cycloalkyl), (C5-6-heterocycloalkyl)-(C i- -alkyl), C ₅ . ₆ -heteroaryl, and -CO-(C _-4 -alkyl)- (C5_6-heterocycloalkyl). In other more particular embodiments, R ^A is independently selected from the group comprising H, -S0 ₂ (Ci _-4 -alkyl), -CO-N(Ci _-4 -alkyl) ₂ , -CO-pipcrazinc- 1 ,4-yl-Ci-4-alkyl- tetrahydrofurane-2-yl, -COO-(Cj ₄ -alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C I _-4 -alkyl-0( C 1 _-4 -alkyl ), -CONH-C , _ ₄ -alkyl-ietrahydiOfurane-2-yl, halogen. C _1-4 - haloalkyl, 3-(C i. ₄ -alkoxy)-phenyl, C | . ₄ -haloalkoxy. -CONH-(C, . ₄ -alkyl), -CONH-(C _3-5 - cycloalkyl), 4-(C 1 - ₄ -alkyl)-piperazine- 1 -yl, 3-pyxidyl, 2-furanyl, -CO-(4-[C | _-4 -alkyl]- pipera/.ine-l -yl), -CO-thien-2-yl. -CO-pyrrol-2-yl. -CO-morpholin-4-yl, piperidin- 1 -yl-, 4-C|. -a!koxycarbony!-pipcridin- ! -yl, C _1-4 -alkyl, C , . ₄ -alkoxycarbony! , mo holin- -y!. 4-pyridyi, - CO-phenyl. -S-(C , _-4 -alkyl ene)-COO-(C , . ₄ -alky1 ). and C _1-4 -alkoxy.

In other more particular embodiments, R ^A is independently selected from the group comprising H, -S0 ₂ (Ci_ ₄ -alkyl), -CO-N(Ci _-4 -alkyl)2, -CO-piperazine-l,4-yl-C _1-4 -alkyl- tetrahydrofurane-2-yl , -COO-(Ci_ ₄ -alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C , -,-alkyl-0(C , ₄ -alk ), -CONH-C, _-4 -alkyl-tetrahydrofurane-2-yl. halogen. C - haloalkyl. 3-(C -alkoxy)-phenyl, C^-haloalkoxy, -CONH-(C, _-4 -alkyl), -CONH-(C _3-5 - cycloalkyl), 4-(C| _-4 -alkyl)-piperazine- 1 -yl, 3-pyridyl, 2-furanyl and ^» CO-(4-[C _1-4 -alkyI]- piperazine-l -yl).

In other even more particular embodiments, R ^A is independently selected from the group comprising H, -S0 ₃ (C |. ₂ -alkyl), -CO-N(Ci. ₂ -alkyl) ₂ , -CO-pipera/.ine- l ,4-yl-Ci ..-..-alkyl- tetrahydroiurane-2-yl. -COO-(C' _! . ₂ -alkyl), -CO-morholine- 1-yl, -CO-pyrrolidine- 1 -yl, - CONH-Ci. ₂ -alkyl-0(C| _-2 -alkyl), -CONH-C _-2 -alkyl-tetrahydrofurane-2-yl, halogen, C,. ₂ - haloalkyl, 3-(C _{! -2} -alkoxy)-phenyl, C , _-4 -haloalkoxy, -CONH-(C i . ₄ -alkyl). -CONH-(C _3- - cycloaJkyl). 4-(Ci _-4 -alkyl)-piperazine- 1 -yl. 3-pyridyl, 2-furanyl, -CO-(4-[Ci. ₄ -alkyl]- pipera/.ine- l -y ), -CO-thien-2-yl. -CO-pyrrol-2-yl, -CO-moipholin-4-yl, piperidin- 1-yl-, 4-C]. ₂ -alkoxycarbonyl -piperidin- 1-yl, C] . ₂ -alkyl, C ₁ . ₂ -a]koxycarbonyl , morpholin-4-yl, 4-pyridyl, - CO-phenyl, -S-(C| . ₂ -alkylene)-COO-(C, . ₂ -alkyl), and C, _-2 -alkoxy.

In other even more particular embodiments, R ^A is independently selected from the group comprising H, -S0 ₂ (Ci _-2 -alkyl), -CO-N(C _1-2 -alkyl) ₂ , -CO-piperazine-1 ,4-yl-Ci _-2 -alkyl- tetrahydrofurane-2-yl, -COO-(Ci. ₂ -alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C 1. ₂ -alkyl-0(C , - ₂ -alkyl). -CONH-C , . ₂ -alkyl-tetrahydrofurane-2-yl, halogen, C _{1 -2} - haloalkyl, 3-(C | . ₂ -alkoxy)-phenyl, C, . ₄ -haloalkoxy, -CONH-(C| . ₄ -alkyl), -CONH-(C _3-5 - cycloalkyl), 4-(Ci-4-alkyl)-piperazine-l-yl, 3-pyridyl, 2-furanyl and -CO-(4- [C i-alk yl ] - piperazinc-l-yl).

In other yet even more particular embodiments, R ^A is independently selected from the group comprising -SO _. e, -CO-NMe?, -C -piperazine- 1.4-yl-CH ₂ -tetrahydrofurane-2-yl, -COO- Et, -CO-morholine-l -yl, -CO-pyrrolidine- l -yl, -CONH-(CH ₂ ) ₂ -OMe, -CONH-CH ₂ - tetrahydrofurane-2-yl, CI, CF ₃ , H, 3-methoxyphenyl, OCF ₃ , -CONH-Me, -CONH- cyclopropyl, 4-mcthyl-piperazine- 1 -yl, 3-pyridyl, 2-furanyl, -CO-(4-ethyl-piperazine- 1 -yl), - CO-thien-2-yl, -CO-pyrrol-2-yl. -CO-morphoiin-4-yl, piperidin- 1 -yl-, 4 elho ycarbony! - piperidin- 1 -yl, methyl, ethoxycarbonyl, morpholin-4-yl, 4-pyridyl, -CO-phenyl, -S-CH ₂ - COO-Et, and methoxy.

In other yet even more particular embodiments, R ^A is independently selected from the group comprising -S0 ₂ Me, -CO-NMe ₂ , -CO-piperazine- 1.4-yl-CH ₂ -tetrahydrofurane-2-yl, -COO- Et, -CO-morholine-l -yl. -CO-pyrrolidine-l-yl, -CONH-(CH ₂ ) ₂ -OMe, -CONH-CH ₂ - tetrahydrofurane-2-yl, CI, CF ₃ , H, 3-methoxyphenyl. OCF ₃ , -CONH-Me, -CONH- cyclopropyl, 4-methyl-piperazine- 1 -yl. 3-pyridyl, 2-furanyl and -CO-(4-ethyl-piperazine- 1 - yl).

In other particular embodiments, R ^A is independently selected from the group comprising - S0 ₂ (C _M -alkyl), -CO-N(C _1-4 -alkyl) ₂ , -CO-NH(Ci _-4 -alkyl), -CO-NH ₂ , -CO-(C ₅ - ₆ - heterocycloalkyl)-Ci_ ₄ -alkyl-(C ₅ -6-heterocycloaikyl), -COO-(C _1-4 -alkyl), -CO-(C _5-6 - heterocyeloalkyl), -CON1 I-C _! . ₄ -alkyl-0(C _i-4 -alkyl). ~CQNH-Ci.4-alkyI-(C ₅ -6-heteroaryf) ₅ H, - CO-(C5-6-heteroaryi), -(Cs-g-heterocycloalkyl), C -alkyloxycarbonyl-substituted C _5- 6- heterocycloalkyl, and Q .4-alkyl.

In other particular embodiments. R ^A is independently selected from the group comprising - S0 ₂ (C _M -alkyl), -CO-N(C -alkyl) ₂ , -CO-NH(C _M -alkyl), -CO-NH ₂ , -CO-(C _5-6 - heterocycloalkyl)-Ci _-4 -alkyl-(C ₅ _ ₆ -heterocycloalkyl), -COO-(C, . ₄ -alkyl), -CO-(C _5-6 - heterocycloalkyl), -CON H-C i .4 -al k yl -0( C 1 -4-alkyl ), and -CON H -C , .4-alkyl -(C ₅ - ₆ -heteiOaryl) .

In other more particular embodiments, R ^A is independently selected from the group comprising -S0 ₂ (Ci _-4 -alkyl), -CO-N(Ci-4-alkyl) ₂ , -CO-piperazine- 1 , 4-yl-Ci. ₄ -alkyl- tetrahydrofurane-2-yl, -COO-(C _1-4 -alkyl), -CO-morholine-l-yl, -CO-pyrrolidinc- 1 -yl, - CONH-C _1-4 -alkyl-0(C 1 - ₄ -alkyl), -CONH-C, 4-alkyl-tetrahydrofuranc-2-yL B, -CO-thicn-2-yl, -CO-pyrrol-2-yl, -CO-morpholin-4-yl, piperidin- l -yl- 4-C -alkyloxycarbonyl-piperidin- 1 -yl. and Ci^-alkyl.

In other more particular embodiments, R ^A is independently selected from the group comprising -S0 ₂ (C _{] -4} -alkyl), -CO-N(C _{1 -4} -alkyl)2, -CO-pipera/ine- 1 ,4-yl-C i _-4 -alkyl- tetrahydrofurane-2-yl, -COO-(C _{i -4} -alkyl), -CO-morholine-l -yl. -CO-pyrrolidine-l -yl, - CO H-C ,_4-alkyl-0(C , _-4 -alkyl ), and -CONH-C , . ₄ -alkyl-tetrahydro turane-2-yl .

In other even more particular embodiments, R ^A is independently selected from the group comprising -S0 ₂ (Ci _-2 -alkyl), -CO-N(C i . ₂ -alkyl) ₂ . -CO-pipera/ine- 1 ,4-yl-C , . ₂ -alkyl- tetrahydrofurane-2-y , -COO-(C] _-2 -alkyl), -CO-morholine-l -yl, -CO-pyrrolidine- 1 -yl, - CONH-Ci _-2 -alkyl-0(Ci _-2 -alkyl), -CONH-Ci. ₂ -alkyl-tetrahydrofurane-2-yl. H, -CO-thien-2-yl, -CO-pyrrol-2-yl, -CO-morpholin-4-yl, piperidin- l -yl- 4-C i _-? -alkyloxycarbonyl-piperidin- 1 -yl, and Ci- ₂ -alkyl.

In other even more particular embodiments, R ^A is independently selected from the group comprising -S0 ₂ (C, _-2 -alkyl), -CO-N(C, . ₂ -alkyl) ₂ , -CO-piperiizine- 1 ,4-yl-C i . ₂ -alkyl- tetrahydrofurane-2-yl, -COO-(Ci. ₂ -alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C , , ₂ -alkyl-0(C , ₂ -alkyl), and -CON I i-C i _-2 -alkyl-tetrahydroi urane-2-yl .

In other yet even more particular embodiments, R ^A is independently selected from the group comprising -S0 ₂ Me, -CO- Me ₂ , -CO-piperazinc- 1 ,4-yl-CH -tetrahydrofuraiie-2-y1 , -COO- Et, -CO-morholine- l -yl, -CO-pyrrolidine-l-yl, -CONH-(CI l ₂ ) ₂ -O e, -CONH-CH ₂ - tetrahydrofurane-2-yl, H, -CO-thicn-2-yl, -CO-pyrrol-2-yl, -CO-m holin-4-yl. piperidin- 1 - yi- 4-ethoxycarbonyl-piperidin- 1 -yl, and methyl.

In other yet even more particular embodiments, R ^A is independently selected from the group comprising -S0 ₂ Me, -CO-NMe ₂ , -CO-pipcrazinc- l ,4-yl-CH2-tetrahydrofurane-2-y , -COO- Et, -CO-morholine- l -yl. -CO-pyrrolidine-l-yl, -CONH-(CH ₂ ) ₂ -OMe, and -CONH-CH ₂ - tctrahydrofurane-2-yl .

In certain embodiments, R' is independently selected from the group comprising H, Ci _-6 - alkyl, Ci. ₆ -haloalkyl, phenyl, naphthyl. C ₅ .6-heteroaryl, C3_7-cycloalkyl and C _{4 7} - heterocycloalkyl. In certain embodiments, R' is independently selected from the group comprising H, C _1-6 - alkyl, Ci_ ₆ -haloalkyl, phenyl, naphthyl, C -6-heteroaryl, C .7-eycloalkyl and C _4-7 - heterocycloalkyl.

In more particular embodiments, R' is Independently selected from the group comprising I I, C| _4-alkyi. phenyl, C _5- 6-heteroaryl comprising 1 to 3 heteroatoms independently selected from the group comprising N, O and S, C3_7-cycioalkyl and C4. 7- heteroeyeloalkyl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S.

In even more particular embodiments, R' is independently selected from the group comprising H, Ci _ ₄ -alkyl, C i _-3 -haloalkyl, phenyl, C5 _-ft -heteroaryl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S, C _3-6 -cycloalkyl and C5-6-heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S,

In even more particular embodiments, R" is independently selected from the group comprising H, methyl, ethyl, i-propyl, n-propyl. i-butyl, n-butyl, t-butyl, CF ₃ , phenyl, pyridine, pyrimidine, pyrrol, furane, thiphene, oxazol, pyrazol, imidazol, isothiazol, Isoxazol, thiazol, oxazol, C ₃ .6-cycloalkyl, thiomorpholine, morpholine, piperidine, piperazine, tetrahydro furane, tetrahydropyrane, pyrrolidine, pyrroline, dihydrofurane, dihydrothiphene, tetrah ydro th i phen e, dihydropyrane, pyrazoline, pyrazolidine, imidazoline, imidazolidine, isothiazoline, isothiazolidine, isoxazoline, isoxazol idine, thiazoline, thiazolidine, oxazoline, oxazoline, and oxazol idine.

In yet even more particular embodiments, R' is independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tetrahydrofuranc, tetrahydrothiphene, phenyl, pyrrolidine, piperazine, piperidine, morpholine, cyclopropyl, cyclobutyl, cyclopentyl, CF ₃ , thienyl, pyrrol and piperidine.

In yet even more particular embodiments, R' is Independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tetrahydrofuranc. tetrahydrothiphene. phenyl, pyrrolidine, piperazine, piperidine, morpholine, cyclopropyl, cyclobutyl, cyclopentyl, and CF ₃ .

In yet even more particular embodiments, R' is independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, i-butyl. t et rahydrofurane, phenyl, pyrrolidine, piperazine, morpholine, cyclopropyl, CF ₃ , thienyl, pyrrole and piperidine.

In yet even more particular embodiments, R ^* is independently selected from the group comprising 11, methyl, ethyl, n-propyl, i-propyl, i-butyl, tetrahydrofurane, phenyl, pyrrolidine, piperazine, morpholine, cyclopropyl and CF

Any of the aforementioned alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl, including any particular or otherwise further specified embodiments thereof (e.g. for alkyl: C _{i -6} -aIkyl, isopropyl, methyl etc.), may independently be substituted with one or more, particularly one to three, more particularly one or two substltuents R", wherein R" is independently selected from the group comprising Ci.4-alkyl, halogen, Cj-4-haloalkyl, OH, C|..i-alkoxy, Ci_ ₄ - haloalkoxy, -N0 ₂ , -CN, -Nib, -N(C _1-4 -alkyl) ₂ , -NH(C, _-4 -alkyl), -NHCO(C _]-4 -alkyl), -CONH ₂ , -CONH(C,. ₄ -alkyl), -CO(C,_ ₄ -alkyl), -COH, -COO(Ci. ₄ -alkyl), -COOH and -CN. In certain embodiments, R" is independently selected from the group comprising H, Ci _-3 - alkyl, chlorine, fluorine, bromine, C|. ₃ -haloalkyl, OH. Ci _-3 -alkoxy, Ci _-3 -haloalkoxy, -NH ₂ , -N(Ci_ ₃ -alkyl) ₂ , -NH(C, _-3 -alkyl), -NHCO(C _1-3 -alkyl), -CONH ₂ , -CONH(C, -alkyl), -CO(C _{r 3} - alkyl), -COH, -COO(Ci _-3 -alkyl), -COOH and -CN. In more particular embodiments, R" is independently selected from the group comprising C 1 . 3-alkyl, chlorine, fluorine, bromine. CF ₃ , OH, OMe, OEt, OCF ₃ , -NH ₂ , -N(Me) ₂ , -N(Et) ₂ , -NH-Me, -NH-Et, -NH-iPr, -NHCO-Me, -CONH ₂ , -CONH-Me, -CONH-Et, -CONH-iPr, acetyl, -COO-Me, -COO-Et, -COOH and -CN. In even more particular embodiments, R" is independently selected from the group comprising methyl, chlorine, fluorine, CF , OH, OMe, OCF ₃ , -NH ₂ , -N(Me) ₂ , -N(Et) ₂ , -NHCO-Me, acetyl, -COO-Me, -COOH and -COOEt. In even more particular embodiments, R" is independently selected from the group comprising methyl, chlorine, fluorine, CF ₃ , OH, OMe, OCF ₃ , -NH ₂ , -N(Me) ₂ , -N(Et) ₂ , -NHCO-Me, acetyl, -COO-Me, and -COOH. In yet even more particular embodiments, R" is independently selected from the group comprising chlorine, fluorine, CF ₃ , OH, OMe, OCF ₃ , -NH ₂ , -N(Me) ₂ , -NHCO-Me, acetyl, -COO-Me, -COOH, -COOEt and methyl.

In yet even more particular embodiments, R" is independently selected from the group comprising chlorine, fluorine, CF , OH, OMe, OCF , -NH ₂ , -N(Me) ₂ , -NHCO-Me, acetyl, -COO-Me, and -COOH.

In yet even more particular embodiments, R" is independently selected from the group comprising H, chlorine, fluorine, CF ₃ , OH, OMe. OCF ₃ , -NH ₂ , -N(Me) ₂ , -COOEt and methyl.

In yet even more particular embodiments, R" is independently selected from the group comprising chlorine, fluorine, CF ₃ , OH, OMe, OCF ₃ , -NH ₂ , and -N(Me) ₂ .

Particularly, the substituent R" is not further substituted.

In a specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 to 48 as described herein in the example section.

In a specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 to 82 as described herein in the example section.

In a specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 4, 5. 6, 7, 8, 9, 10, 1 1 , 14, 17, 18. 19. 21 , 22, 23, 24, 25, 26, 27. 28, 29, 30, 31 , 34, 35, 37. 38. 39, 40, 41 , 42, 44, 45, 46. 47, and 48 to 71 as described herein in above Table 1.

In a more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 , 2, 3, 4, 6, 7, 8, 9, 10, 14, 17, 18, 19, 21 , 22, 23. 24, 25, 27, 28, 30, 34, 35. 38, 39, 40, 41 , 42, 45. 46 47, and 48 to 65 as described herein in above Table 1 .

In an even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 , 3, 6, 7, 8, 9, 10, 19, 22, 23, 25, 30, 35, 38, 42, 45 47 and 48 to 51 as described herein in above Table 1.

In another specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 , 2, 3, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16. 1 8, 19, 20, 21 , 22, 23, 24, 25, 30, 31 , 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46 and 47 as described herein in above Table 1.

In another more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1. 2, 3, 5, 6. 7, 8, 9, 10, 1 1 , 12, 13, 14, 19, 22, 23, 25, 35, 41 , 45, 46 and 47 as described herein in above Table 1.

In another even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 3. 7, 8, 9, 10, 22, 23, 25 and 35 as described herein in above Table 1 .

In another yet even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 1 , 42, 45, 46, 47, 50, 54, 55 and 62 as described herein in above Table 1. In a specific embodiment, the compounds of the present Invention are selected from the group comprising compounds 1 , 2, 3, 5, 6, 7, 8, 9, 1 0. 1 1 , 14. 17, 1 8, 19, 21 , 22, 23, 24, 25, 26, 27. 28. 29, 30, 3 1 , 34, 35, 37, 38, 39, 40, 41 , 42, 44, 45, 46, and 47 as described herein in above Table 1 . In a more specific embodiment, the compounds of the present invention are selected from the group comprising compounds I , 2, 3, 6, 7, 8, 9, 10, 14, 17, 18, 19, 21 , 22, 23, 24, 25, 27, 28, 30, 34, 35, 38, 39, 40, 41 , 42, 45, 46 and 47 as described herein in above Table 1. In an eve more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 , 3, 6, 7, 8, 9, 10, 19, 22, 23, 25, 30, 35, 38, 42, 45 and 47 as described herein in above Table 1. In another specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46 and 47 as described herein in above Table 1. In another more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 19, 22, 23, 25,

35, 41, 45, 46 and. 47 as described herein in above Table 1.

In another even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 3, 7, 8, 9, 10, 22, 23, 25 and 35 as described herein in above Table 1.

In another yet even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 9, 23 and 25 as described herein in above Table 1, yet. even more specifically compound 23.

In another yet even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 5, 9, 23 and 25 as described herein in above Table 1.

In another yet even more specific embodiment, the compound of the present invention is compound 5 in above Table 1.

In certain embodiments, the following compounds are excluded:

2-(2,3-dihydro- 1 -benzofuran-5-yl)-N-[3-(piperazin- 1 -yl)pyridin-2-yl]- 1 ,3-thiazole-4- carboxamide;

tert-butyl 4- {2-[2-(2,3-dihydro- 1 -bcn/.ofuran-5-yl)- 1 ,3-thiazole-4-amido]pyridin-3-yl } piperazine- 1 -carboxylate; and 2-(2,3-dihydro- l -benzofuran-5-yl)-N-ethyl-N-(2- {[(l S)- l -phenyl ethyl] amino } pyrimidin-4- yl)- 1 ,3-thiazole-4-carboxamide.

In certain particular embodiments alkyl encompasses a linear or branched Ci-C ₆ alkanyl, C ₂ - C(, alkenyl, C2-C ₆ alkynyl; the total number of ring atoms in the aryl group is 6 to 14;

the total number of ring atoms in the heteroaryl group is 5 to 1 4; cycloalkyl comprises 3 to 10 carbon atoms; heterocycloalkyl is a 5- to 10-membered mono- or polyeyclic ring system; haloalky! denotes an alkyl group wherein one or more of the hydrogen atoms on the hydrocarbon chain are replaced by halogen atoms; alkoxy denotes an O-alkyl group, the alkyl group being as defined above; alkyl thio denotes an -S-alkyl group, the alkyl group being as defined above; haloalkoxy denotes an O-haloalkyl group, haloalkyl group being as defined above; alkylamino denotes a NH-alkyl or N-di alkyl group, the alkyl group being as defined above; and said alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more suhstituents R". 14. A pharmaceutical composition comprising a compound according to the present invention, in particular according to any of the above items 1 to 13 or a physiologically functional derivative, solvate or salt thereof and one or more pharmaceutically acceptable excipients for the use in the treatment or prevention of a disease or medical condition caused by a viral infection. Furthermore, the present invention relates to a method of treatment or prevention of the medical conditions specified herein, which comprises the administration of an effective amount of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof to a subject in need thereof.

Furthermore, the present invention relates to the use of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof in the treatment or prevention of the medical conditions specified herein.

Furthermore, the present invention relates to the use of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof for the manufacture of a medicament for use in the treatment or prevention of the medical conditions specified herein. 15. A method of treatment or prevention of a medical condition caused by a viral infection, which comprises the administration of an effective amount of a compound according to the present invention, in particular according to any of the above items 1 to 13, or a physiologically functional derivative, solvate or salt thereof to a subject in need thereof. 16. Use of a compound according to the present invention, in particular according to any of the above items 1 to 13, or a physiologically functional derivative, solvate or salt thereof in the manufacture of a medicament for the treatment or prevention of a medical condition caused by a viral infection.

17. Use of a compound according to the present invention, in particular according to any of the above items 1 to 13, or a physiologically functional derivative, solvate or salt thereof for the treatment or prevention of a medical condition caused by a viral infection.

18. The compound for the use, the pharmaceutical composition, the method, the use of said compound for treatment or the use of said compound for the manufacture of a medicament according to the present invention, in particular according to any of the above items 1 to 17, wherein said medical condition caused by a viral infection is caused by an infection with a virus from the family of herpesviridae. more particularly a virus selected from the group consisting of HCMV and HSV, even more particularly HCMV, and in another embodiment even more particularly HSV,

Particularly in the context of the present invention, HSV is selected from the group comprising HSV- 1 and HSV-2.

19. The compound for the use, the pharmaceutical composition, the method, the use of said compound for treatment or the use of said compound for the manufacture of a medicament according to the present invention, in particular according to any of the above items 1 to 1 7, wherein said medical condition caused by a viral infection ith HSV or HCMV.

The following definitions are meant to further define certain terms used in the context of the present invention. If a particular term used herein is not specifically defined, the term should not be considered to be indefinite. Rather, such terms are to be construed in accordance with their meaning as regularly understood by the skilled artisan in the field of art to which the invention is directed, particularly in the field of organic chemistry, pharmaceutical sciences and medicine. As used herein, a "ring atom" represents an atom which is part of the cyclic structure of a ring or ring system, wherein this definition does not include hydrogen atoms or substituents bound to the ring or ring system. For example, a pyridine group comprises 6 ring atoms, i.e. one N atom and five C atoms; In the context of the present invention, and for reasons of legibility, chemical group names such as "aikyF, "aryl", "phenyl", "heteroaryl", "cycloalkyi", "heterocyclyl", etc., depending on the respective particular context, are meant to include terminal groups and connecting groups which are often referred to as "...ene" groups, such as for example "alkylene", "arylene", etc. Moreover, in the context of the present invention, the suffix ^"' -νΓ is in many cases omitted, which is not to be understood to delimit chemical names comprising said suffix from chemical names not comprising said suffix; for example "furyl", "furanyl" and "furane" are meant to be used interchangeably.

As used herein, the term "X'-azol moiety" refers to the below chemical entity, which is part of formular (I) according to the present invention:

As used herein, an alkyl group particularly encompasses alkanyl, alkenyl, alkynyl, wherein alkanyl means a completely saturated hydrocarbon chain, alkenyl means a hydrocarbon chain comprising at least one carbon-carbon double bond, alkynyl means a hydrocarbon chain comprising at least one carbon-carbon triple bond (including a hydrocarbon chain comprising one or more carbon-carbon double bonds and at least one carbon-carbon triple bond). In the context of the present invention, an alkanyl group, if not stated otherwise, particularly denotes a linear or branched Ci-CValkanyl, more particularly a linear or branched Ci-C ₅ -aikanyi, even more particularly a linear or branched Ci-C ₄ -alkanyl; an alkenyl group, if not stated otherwise, particularly denotes a linear or branched CVCValkenyl, more particularly a linear or branched CVCValkenyl, even more particularly ethenyl; and an alkynyl group, if not stated otherwise, particularly denotes a linear or branched CVCValkynyl group, more particularly a linear or branched CVCValkynyl, even more particularly ethynyl. In certain particular embodiments the alky! group is selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tcrt-butyl. pentyl, hexyl, ethenyl, ethynyl, propen-l -yl. propen-2-yl, propen-3-yl. -C≡C-CH ₃ , and -CH ₂ -C≡CH. The alkyl, alkanyl, alkenyl, and alkynyl groups as defined above, including the groups enumerated as examples and particular or otherwise farther defined embodiments thereof, are optionally substituted by one or more substituents R".

As used herein, the term "aryl" particularly denotes an aromatic mono-or polycyclic hydrocarbon ring system, which may optionally be fused to one or more cycloalkyl or heterocycloalkyl rings, and wherein the total number of ring atoms in the aryl group is 6 to 14, particularly 6 to 10, more particularly 6. The point of attachment of said aryl group to the central moiety may be located on the aromatic mono-or polycyclic hydrocarbon ring system r on the optionally fused cycloalkyl or heterocycloalkyl ring. Examples of the aryl group are phenyl, naphthyl, indenyl, azulenyl, fluorenyl, 1 ,2-dihydronaphthyl. 1,2,3,4- tetrahydronaphthyl , 2,3-dihydroindenyl, 1 ,5-dihydro-s-indacenyl, 1,6-dihydro-as-indacenyl, 1 H-cyclopenta[a]naphthyl and 1 H -cyclo penta j b j naphthyl , phenalenyl, phenanthrenyl anthracenyl, 1.6-dihydropentalcnyl, 1 ,6a-dihydropentalenyl, 1.2,3 ,4-tetrahydroanthracenyl , 1 ,2,3 ,4-tetrahydrophenanthrenyl, 2.3-dihydro-l H-cyclopenta[a]naphthalenyl, 2,3-dihydro- l H- cyclopenta[b]naphthalenyl, 2,3-dihydro- 1 H -phenalenyl, 2,3 -dihydrobenzo[b]thiophcnyl- 1.1 - dioxide, 1.2,3.4-tetrahydroisoquinolinyl. 1 ,2,3,4-tetrahydroquinolinyl, 2,3- dihydrobcnzo[b][ 1 ,4]dioxinyl, 2,3-dihydrobcnzo[b]thiophenyl, 2,3 -dihydrobenzofuranyl , benzo[d][ 1.3]dioxolyl, chromanyl, indazolinyl and indolinyi. In particular embodiments, the aryl group is phenyl, 2,3-dihydrobenzo[b][l ,4]dioxinyl, 2.3-dihydrobenzofuranyl or benzo[d][ l,3]dioxolyl, more particularly phenyl. The aryl groups as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R".

As used herein, the term "halophenyf ' particularly denotes a phenyl group substituted with one or more halogen atoms, particularly with one halogen atom. As used herein, the term "heteroaryl" particularly denotes an aromatic mono-or polycyclic hydrocarbon ring system wherein one or more carbon atoms are replaced by heteroatoms independently selected from the group comprising O, N and S, wherein the aromatic mono-or polycyclic hydrocarbon ring system may optionally be fused to one or more cycloalkyl or heterocycloalkyl rings, and wherein the total number of ring atoms in the heteroaryl group is 5 to 14, particularly 5 to 10, more particularly 5 or 6. The point of attachment of said heteroaryl group to the central moiety may be located on the mono-or polycyclic aromatic hydrocarbon ring system or on the optionally fused cycloalkyl or heterocycloalkyl ring. Examples of the heteroaryl group are furan-2-yl. furan-3-yl, thiophen-2-yl, thiophen-3-yl, thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, oxa/ol-4-yl, oxazol-5-yl, isoxazol-4-yl. isoxazol-5-yl, pyrazin-2- yl, pyridin-2-yl. pyridin-3-yl, pyridin-4-yl, pyrrol -2-yl. 1 ,2.3-thiadiazol-5-yl, 1 ,2,4-thiadiazol- 3-yl, benzothiophen-3-yl, l ,2,3-triazol-4-yl, l ,2,4-triazol-5-yl, quinolin-2-yl, , thiazol-2-yl, thiazol-5-yl, isothiazol-3-yl. isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, isoxazol-3-yl, 1 ,2,4- oxadiazol-3-yl, l ,2,4-oxadiazol-5-yl, 1 ,2,5-oxadiazol-3-yl. 1 ,2,5-oxadiaz.ol-4-yl, 1.2,3- oxadiazol-4-yl, l ,2,3-oxadiazol-5-yl, 1 ,3,4-oxadiazol-2-yl, 1 ,2,4-thiadiazol-5-yl, 1 ,2,5- thiadiazol-3-yl, l ,2,5-thiadiazol-4-yl, 1 ,3.4-thiadiazol-2-yl, l ,2,3-thiadiazol-4-yl, pyrrol- 1 -yl, pyrrol-3-yl, pyrazol-l -yl, purin-2-yl , purin-6-yl, purin-8-yl, purin- -yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, imidazol- l -yl, imidazol-2-yl, imidazol-4-yl, l ,2,3-triazol-5-yl, l ,2,4-triazol-3-yl, furan-2-yl, benzo[b]furanyl, quinolinyl, isoquinolinyl, indol-2-yl, indol-3-yl, isoindol- l -yl, isoindol-3-yl, indol-2-yi.indol-3-yl, purin-2-yl. In particular embodiments, the heteroaryl group is selected from the group comprising furan-2- yl, thiophen-3-yl, pyiimidin-2-yl, or pyrimidin-6-yl, and pyridine-4-yl. In other particular embodiments, the heteroaryl group is selected from the group comprising furan-2-yl, thiophen-3-yl, pyrimidin-2-yl, pyrimidin-6-yl, pyridine-4-yl, l//-imidazol-2-yl, lH- 1 ,2,4- triazol-5-yl, I H-bcnzo | r/j imidazol-2-yl , pyridin-2-yl, lH-imidazol-2-yl, 1 ,3,4-thiadiazol-2-yl, lH-pyrazol-3-yl, l ,3-thiazol-2-yl, 1 ,2,4-thiadiazol-3-yl, l,3,4-thiadiazol~2-yl, 1 ,2,4- thiadiazol-5-yl, 1.3-oxazol-2-yl and l ,2.4-oxadiazol-3-yl.

The heteroaryl groups as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R",

As used herein, the term "cycloalkyl" particularly denotes a non-aromatic, mono- or polycyclic completely saturated or partially unsaturated hydrocarbon ring system. Said cycloaikyl is particularly mono- or bicyclic, more particularly monocyclic. Said cycloaikyl is particularly completely saturated. Said cycloaikyl particularly comprises 3 to 10 carbon atoms, more particularly 3 to 7, even more particularly 3 to 6 carbon atoms. Even more particularly, said cycloaikyl is selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohe.xyl, eycloheptyl, 1 -norbornyl, 2-norbonryl, 7-norbornyl, 1-adamantyl, and 2-adamantyl, yet even more particularly said cycloaikyl is cyclohexyl. The cycloaikyl groups as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R ^* . and 0, 1 or 2, particularly 0 or 1, more particularly 0 of the ring carbon atoms are attached to an oxygen atom via a double bond to form a carbonyl group.

As used herein, the term "heterocyeloalkyl" particularly denotes a non-aromatic mono- or polycyclic completely saturated or partially unsaturated hydrocarbon ring system, wherein one or more, particularly 1 to 3, more particularly 1 or 2 of the ring carbon atoms are replaced by a heteroatom independently selected from N, O, or S. Said heterocyeloalkyl is particularly mono- or bicyclic, more particularly monocyclic. Said heterocyeloalkyl is particularly completely saturated. Said heterocyeloalkyl particularly is a 5- to 10-membered mono- or polycyclic ring system, more particularly 5- to 7-membered monocyclic ring system, even more particularly 5- or 6-membered monocyclic ring system. Even more particularly said heterocyeloalkyl is selected from the group comprising morpholinyl, piperidinyl, pyrrolidinyl, and piperazinyl. The heterocyeloalkyl group as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents ' as described herein, and 0, 1 or 2, particularly 0 or 1, more particularly 0 of the ring carbon atoms are attached to an oxygen atom via a double bond to form a carbonyl group.

As used herein, the term "halo" or "halogen" particularly independently denotes fluorine, chlorine, bromine or iodine, more particularly bromine, chlorine or fluorine, even more particularly chlorine or fluorine.

As used herein, the term "haloalkyl" denotes an alkyl group wherein one or more, particularly at least hall; more particularly all of the hydrogen atoms on the hydrocarbon chain are replaced by halogen atoms. . The haloalkyl group is particularly selected from the group comprising -C(R ^I0 ) ₃ , -CH ₂ -C(R ¹⁰ ) ₃ , -C(R ¹⁰ ) ₂ -CH ₃ , -C(R ¹⁰ ) ₂ -C(R ¹⁰ ) ₃ , -C(R ¹⁰ ) ₂ -CH(R ¹⁰ ) ₂ , - CH ₂ -CH(R ^,0 ) ₂ , -CH(R ¹⁰ )-C(R ^S0 ) ₃ , -CH(R ^{I 0} )-CH ₃ , and -C ₂ H ₄ -C(R ¹⁰ ) ₃ , more particularly -

C(R"')3. wherein R ¹⁰ represents halogen, particularly F. More particular haloalkyl groups are - CF ₃ , -CH2CF3, and CF ₂ C1. As used herein, the term "alkoxy" denotes an O-alkyl group, the alkyl group being defined as defined above. The alkoxy group is particularly selected from the group comprising mcthoxy and ethoxy.

As used herein, the term "alkylthio" denotes an -S-alkyl group, the alkyl group being as defined above.

As used herein, the term "haloalkoxy" denotes an O-haloalkyl group, haloalkyl group being defined as defined above. The haloalkoxy group is particularly selected from the group comprising -OC(R ¹⁰ ) ₃ , -OCR ¹⁰ (R ^{I 0'} ) ₂ , -OCH ₂ -C(R ¹⁰ ) ₃ , and -OC ₂ H ₄ -C(R ¹⁰ ) ₃ , wherein R ¹⁰ , R ¹ " ^' represent F, CI, Br or I, particularly F.

As used herein, the term "alkylamino" denotes a NH-alkyl or N-dialkyl group, the alkyl group being as defined above. As used herein, the term "arylalkyl" or "aralkyi" particularly denotes a linear or branched Cp

C _f ,-alkyl, more particularly Cj _-4 -alkyl, even more particularly C]. ₂ -alkyl, yet even more particularly methyl, wherein "alkyl" is as defined herein, substituted with at least one, particularly exactly one, aryl group as defined herein. Exemplary arylalkyl groups include styryl, benzyl, phenylethyl, particularly the arylalkyl group is styryi or benzyl, particularly optionally substituted at its phenyl part as defined above for the aryl group.

Where chemically feasible from the viewpoint of molecule stability and/or chemical valence rules, a nitrogen heteroatom as defined herein, e.g. in the context of "heteroaryl" and "heterocycle", may include the N-oxide.

Where chemically feasible from the viewpoint of molecule stability under physiological conditions and/or chemical valence rales, the definition of a sulfur heteroatom as defined herein, e.g. in the context of "heteroaryl" and "heterocycle", may include the sulfur oxide and/or the sulfur dioxide, respectively. For sake of completeness, it is mentioned that "morpholine-4-carbonyl" is a group -CO- morpholine-4-yl. As used herein the term "substituted with" or ..substituted by" means that one or more hydrogen atoms connected to a carbon atom or heteroatom of a chemical group or entity arc exchanged with a substituent group, respectively; e.g. substituted aryl comprises 4- hydroxyphenyl. wherein the H-atom in the 4-position of the phenyl group is exchanged with a hydroxy! group. Said hydrogen atom(s) to be replaced may be attached to a carbon atom or heteroatom, and may be expressly shown in a specific formula, such as for example in an -NH- group, or may not expressly be shown but intrinsically be present, such as for example in the typical "chain" notation which is commonly used to symbolize e.g. hydrocarbons. The skilled person will readily understand that particularly such substituents or substituent patterns are excluded, which lead to compounds witch are not stable and/or not accessible via the synthesis methods known in the art.

Unless specified otherwise, references to the compounds according to the present invention include the pharmaceutically acceptable derivatives, solvates or salts thereof as described herein, as well as to salts of said pharmaceutically acceptable derivatives, solvates of salts and pharmaceutically acceptable derivatives, and optionally solvates of salts of pharmaceutically acceptable derivatives.

As used herein, the term "pharmaceutically acceptable derivative ^" ' of a compound according to the present invention is for instance a prodrug of said compound, wherein at least one of the following groups are derivatized as specified in the following: A carboxylic acid group is derivatized into an ester, a hydroxy! group is derivatized into an ester, a carboxylic acid is derivatized into an amide, an amine is derivatized into an amide, a hydroxy! group is derivatized into a phosphate ester. To clarify, the term "pharmaceutically acceptable derivative" is in certain embodiments analogous to the term "physiologically functional derivative ^" .

As used herein, the term "tautomer" used in reference to the compounds according to the present invention, in particular includes tautomers that typically form with respect to substituted benzi mid azoic groups. As an illustration two tautomeric forms of an exemplary substituted benzimidazole moiety, as is present in the compounds according to the present invention, are shown:

The compounds according to the present invention are to be understood to comprise all tautomeric forms thereof, even if not expressly shown in the formulae described herein, including formula (I). Throughout this specification, whenever a chemical formula, generic or otherwise, discloses a compound having a 4H-1 .2.4-triazole moiety that is at least partially unsubstituted, as shown on the left-hand side of the above exemplary illustration, said chemical formula it is to be understood to implicitly also relate to compounds wherein said moiety is tautomerized to form the structure as shown on the right-hand side of the above exemplary illustration.

The compounds of formula (I) as defined herein are to be understood to encompass, where applicable, all stereoisomers of said compounds, unless specified otherwise. The term "stereoisomer" as used herein refers to a compound with at least one stereogenic centre, which may be R- or S-configured, as defined by the according IUPAC rules, and encompasses enantiomcrs and diastereomers as commonly understood by the skilled person. It has to be understood, that in compounds with more than one stereogenic centre, each of the individual stereogenic centres may independently from each other be R- or S-configured. The term "stereoisomer" as used herein also refers to salts of the compounds herein described with optically active acids or bases.

In the present invention, the salts of the compounds according to the present invention are in particular embodiments pharmaceutically acceptable salts of the compounds according to the present invention. Pharmaceutically acceptable salts are such salts which are usually considered by the skilled person to be suitable for medical applications, e.g. because they are not harmful to subjects which may be treated with said salts, or which give rise to side effects which arc tolerable within the respective treatment. Usually, said pharmaceutically acceptable salts are such salts which are considered as acceptable by the regulatory authorities, such as the US Food and Drug Administration (FDA), the European Medicines Agency (EM A), or the Japanese Ministry of Health. Labor and Welfare Pharmaceuticals and Medical Devices Agency (PMDA). However, the present invention in principle also encompasses salts o the compounds according to the present invention which are as such not pharmaceutically acceptable, e.g. as intermediates in the production of the compounds according to the present invention or physiologically functional derivatives thereof, or as intermediates in the production pharmacologically acceptable salts of the compounds according to the present invention or physiologically functional derivatives thereof.

In each case, the skilled person can readily determine whether a certain compound according to the present invention or pharmaceutically acceptable derivative there f can form a salt, i.e. whether said compound according to the present invention or pharmaceutically acceptable derivative or solvate thereof has a group which may carry a positive or negative charge, such as e.g. an amino group, a carboxylic acid group, etc..

Exemplary salts of the compounds of the present invention are acid addition salts or salts with bases, particularly pharmacologically tolerable inorganic and organic acids and bases customarily used in pharmacy, which are either water insoluble or. particularly, water-soluble acid addition salts. Salts with bases may - depending on the substituents of the compounds of the present invention - also be suitable.

Pharmacologically intolerable salts, which can be obtained, for example, as process products during the preparation of the compounds according to the invention on an industrial scale, are also encompassed by the present invention and, if desired, may be converted into pharmacologically tolerable salts by processes known to the person skilled in the art.

According to expert's knowledge the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore solvates and in particular hydrates of the compounds of the present invention as well as solvates and in particular hydrates o the salts and/or physiologically functional derivatives of the compounds of the present invention. More particularly the invention encompasses hydrates of the compounds, salts and/or physiologically functional derivatives according to the present invention, comprising one, two or one half water molecule, with respect to their stoichiometry. As used herein, a "solvate" is a complex formed in the crystalline state between one or more compounds according to the present invention (or pharmaceutically acceptable derivative or salt thereof) and one or more solvent molecules. In certain embodiments, such solvates are 1 :2, 2: 1 or 1 : 1 , more particularly 1 : 1 stoichiometric complexes. Furthermore, in certain embodiments, complexes, such solvates are formed with a solvent selected from the group comprising water, methanol, ethanol or propanol, particularly water, methanol or ethanol, more particularly water (the latter is typically also known under the term "hydrate").

As used herein, the term "room temperature", "rt" or "r.t." relates to a temperature of about 25°C, unless specified otherwise.

As used herein, the term "stable" particularly relates to a compound in which the chemical structure is not altered when the compound is stored at a temperature from about -80 °C to about +40 °C, more particularly from about -80 °C to +25 °C in the absence of light, moisture or other chemically reactive conditions for at least one week, more particularly at least one month, even more particularly at least six months, yet even more particularly, at least one year, and/or a compound which under lUPAC standard conditions and in the absence of light, moisture or other chemically reactive conditions maintains its structural integrity long enough to be useful for therapeutic or prophylactic administration to a patient, i.e. at least one week. Stable in this context mean that under the aforementioned conditions and time periods and compared with the the timepoint 0, i .e. when it was produced, the amount of impurities has increased by less than 2%, particularly less than 1 % more particularly less thatn 0.5%, which can e.g. be determined by analytic HPLC or LC-MS, or the like. Compounds which are not stable as described above are usually to be considered not encompassed by the present invention. In particular, such compounds which at IUPAC standard conditions spontaneously decompose within a period of less than one day are regarded as not being stable compounds. The skilled person will readily recognize, based on his general knowledge in his field of expertise, which compounds and which substitution patterns result in stable compounds.

As used herein, the term "treatment" of a disease or medical condition includes complete or partial healing of a disease, prevention of a disease, alleviation of a disease or stop of progression of a given disease.

"Prevention" in particular includes that the compounds of the present invention are administered to a subject before the viral infection occurs. "Prevention" further includes that the compounds of the present invention are administered to a subject after the viral infection occurs, but before the onset of symptoms of the disease or medical condition.

In the context of the present invention, the "subject" is particularly a mammal, more particularly a human subject. As used herein, the term "medicament" includes the compounds of the present invention, pharmacologically acceptable salts or physiologically functional derivatives thereof, which are to be administered to a subject in pure form, as well as compositions comprising at least one compound according to the present invention, a pharmacologically acceptable salt or physiologically functional derivative thereof, which is suitable for administration to a subject. The compounds according to the present invention and their pharmacologically acceptable salts and physiologically functional derivatives can be administered to animals, particularly to mammals, and in particular to humans as therapeutics per se, as mixtures with one another or particularly in the form of pharmaceutical preparations or compositions which allow enteral (e.g. oral) or parenteral administration and which comprise as active constituent a therapeutically effective amount of at least one compound according to the present invention, or a salt or physiologically functional derivative thereof, in addition to e.g. one or more components selected from the group comprising customary adjuvants, pharmaceutically innocuous excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries. The pharmaceutical compositions, medical uses and methods of treatment according to the present invention may comprise the more than one compound according to the present invention.

Pharmaceutical compositions comprising a compound according to the present invention, or a pharmaceutically acceptable salt or physiologically functional derivative may optionally comprise one or more further therapeutically active substances which are not compounds of the present invention. As used herein, the term "therapeutically active substance" specifies a substance which upon administration can induce a medical effect in a subject. Said medical effect may include the medical effect described herein for the compounds of the present invention, but may also, in the case of therapeutically active substances which are to be co- administered with the compounds according to the present invention, include other medical substances, such as for example but not exclusively adamantin, rimantadin, ose amivir, zanamivir, zidovudine, didanosine, zalcitabine, stavudine, abacavir, entecavir, apricitabine, tenofovir, adefovir, efavirenz, nevirapine, delafiridine, etravirinc. rilpvirine and lamivudine, emtricitabine, ribavirin, interferone alpha (pegylated or non-pegylated), telbivudin. aciclovir, valaciclovir, ganciclovir, valganciclovir, brivudin, penciclovir. The term "pharmaceutically acceptable" is well known to the skilled person and particularly means that the respective entity is not harmful to the subject to which the entity or the composition comprising the entity is administered, that said entity is stable and that said entity is chemically compatible (i.e. non-reactive) with other ingredients of the respective pharmaceutical composition. Medicaments and pharmaceutical compositions according to the present invention, comprising at least one compound according to the present invention or a pharmacologically acceptable salt or a physiologically functional derivative therof include those suitable for oral, rectal, bronchial, nasal, topical, buccal, sub-lingual, vaginal or parenteral (including transdermal, subcutaneous, intramuscular, intrapulmonary, intravascular, intracranial, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by controlled release (e.g. sustained release, pH-controlled release, delayed, release, repeat action release, prolonged release, extended release) systems, particularly for oral, topical or rectal administration. Suitable examples of controlled release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules or colloidal drug carriers e.g. polymeric nanoparticles, or controlled release solid dosage forms, e.g. core tablets or multi-layer tablets.

The production of medicaments or pharmaceutical compositions comprising the compounds according to the present invention and their application can be performed according to methods which are well-known to the medical practitioner.

Pharmaceutically acceptable carriers used in the preparation of a pharmaceutical composition or medicament comprising a compound according to the present invention, a pharmacologically acceptable salt or physiologically functional derivative thereof, can be either solid or liquid. Solid form pharmaceutical compositions comprising a compound according to the present invention, a pharmacological 1 y acceptable salt or physiologically functional derivative thereof, include powders, tablets, pills, capsules, sachets, suppositories, and dispersible granules. A solid carrier may comprise one or more components, which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The tabletting mixture can be granulated, sieved and compressed or direct compressed. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymcthylccllulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, sachets and lozenges are included. Tablets, powders, capsules, pills, sachets, and lozenges can be used as solid forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glyceride or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into conveniently sized moulds, allowed to cool, and thereby to solidify. Compositions suitable for vaginal administration may be presented as peccaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Liquid preparations include solutions, suspensions, and emulsions, for example, water or water- propylcnc glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution. The compounds according to the present invention may be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre- filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for re-constitution with a suitable vehicle, e.g. sterile, pyrogen- free water, before use. Aqueous solutions suitable for oral administration can be prepared by dissolving the active component in water and adding for example suitable colorants, flavours, stabilizing and thickening agents, as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.

Also included are solid form preparations, which are intended to be converted, shortly before administration, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, for example colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

In an embodiment f the present invention the medicament is applied topically, e.g. in the form of transdermal therapeutic systems (e.g. patches) or topical formulations (e.g. liposomes, cremes, ointment, lotion, gels, dispersion, suspension, spray, solution, foam, powder). This may be suitable to reduce possible side effects and. where appropriate, limit the necessary treatment to those areas affected.

Particularly the medicament may comprise carrier materials or excipients, including but not limited to a lipophilic phase (as for example Vaseline, paraffines, triglycerides, waxes, polyalcylsiloxanes), oils (olive oil, peanut oil. castor oil, triglyceride oil), cmulsificr (as for example lecithin, phosphat idylgl ycerol es, alkyl alcohols, sodium lauryl sulfate, polysorbats, Cholesterol, sorbitan fatty acid ester, polyoxyethylene fatty acid glycerol and -ester, poloxamers), preservatives (for instance benzalkonium chloride, chlorobutanol, parabene or fhiomersal), flavouring agents, buffer substances (for example salts of acetic acid, citric acid, boric acid, phosphoric acid, tatric acid, trometamole or trolamine), solvents (for instance po 1 yethyi eng) ycol s, glycerol, ethanol, isopropanol or propyleneglycol) or solubilizers, agents for achieving a depot effect, salts for modifying the osmotic pressure, carrier materials for patches (for instance polypropylene, ethy!ene-vinylacetat-copolymer, polyacrylates, silicon) or antioxidants (for example ascorbate, tocopherol, butylhydroxyanisole, gallic acid esters or butylhydroxytoluol). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be fonnulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

Compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth: pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Solutions or suspensions may be applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.

Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propel] ant such as a chlorofluorocarbon (CFC), for example dichlorodiftuoromcthane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose f drug may be controlled by provision of a metered valve.

Alternatively the medicament may be provided in the form of a dry powder, for example a powder mix o the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form, for example in capsules or cartridges of, e.g., gelatine, or blister packs from which the powder may be administered by means of an inhaler. in compositions for administration to the respiratory tract, including intranasal compositions. the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by microni/.ation.

When desired, compositions adapted to give sustained release of the active ingredient may be employed. The pharmaceutical preparations are particularly in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, sachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are particular compositions.

Further details on techniques for formulation and administration may be found in the 21 ^st edition of Remington's Pharmaceutical Sciences (Maack Publishing Co. Easton, Pa.).

The compounds of the present invention may be used in combination with radiation therapy, or in combination with radiation therapy and other active compounds, already known for the treatment of the medical conditions disclosed herein, whereby a favourable additive or amplifying effect is noticed. To prepare the pharmaceutical preparations, pharmaceutically inert inorganic or organic excipients can be used. To prepare pills, tablets, coated tablets and hard gelatine capsules, for example, lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts, etc. can be used. Excipients for soft gelatine capsules and suppositories are, for example, fats, waxes, semi-solid and liquid polyols, natural or hardened oils etc. Suitable excipients for the production of solutions and symps are, for example, water, sucrose, invert sugar, glucose, polyols etc. Suitable excipients for the production of injection solutions are, for example, water, alcohols, glycerol, polyols or vegetable oils.

The dose can vary within wide limits and is to be suited to the individual conditions in each individual case. For the above uses the appropriate dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired, in general, however, satisfactory results are achieved at dosage rates of about 1 to 100 mg kg animal body weight particularly 1 to 50 mg/kg. Suitable dosage rates for larger mammals, for example humans, are of the order of from about 10 mg/day to 500 mg/day, conveniently administered once, in divided doses 2 to 4 times a day, or in sustained release form. The compounds of the present invention are suitable for the treatment or prevention of a disease or medical condition caused by a viral infection. It is apparent that the embodiments of the present invention as described herein may be combined to form further particular embodiments of the present invention.

Examples Methods for the synthesis of compounds of the present invention is known to the skilled person and described in WO 2014/202638 Al , as well as their potency in the inhibition of DYRK Kinase, and the hedgehog pathway.

Cell culture and virus: Primary human foreskin fibroblasts (HFF) were cultivated in minimal essential medium (MEM) containing 5% (vol/vol) fetal calf serum. Infection analysis was restricted to cell passage numbers below 20. HCMV strain AD 169 was grown in HFF and quantitated for infectivity by a plaque reduction assay. Aliquots were stored at -80°C.

GFP-based antiviral assay:

HFF were cultivated in 12-well plates to 90% confluency and used for infection with AD 169- GFP virus at a tissue culture infective dose of 0.5 (GFP-TCID50 0.5, referring to an MOI of 0.002 as determined by plaque assay titration). Virus inoculation was performed as described above. Then infected cell layers were incubated with 2.5 ml of MEM containing 5% (vol/vol) fetal calf serum with or without the respective test compound. Infected cells were incubated at 37°C under a 5% CO: atmosphere for 7 days. For lysis, 200 ml of lysis buffer (25 mM Tris [pH 7.8], 2 mM dithiothreitol [DTT], 2 mM trans- 1,2-di minocyclohexane-N,N,N9,N9- tetraacetic acid, 1% Triton X-100, 10% glycerol) was added to each well and incubated for 10 min at 37°C, followed by a 30-miii incubation at room temperature on a shaker. Lysates were eentriftiged for 5 min at 15,000 rpm in an Eppendorf centrifuge to remove cell debris. One hundred microliters of the supernatants was transferred to an opaque 96-well plate for automated measuring of GFP signals in a Victor 1420 Multilabel Counter (Wallac). The efficacy of the test compounds against virus was determined by comparing the compound- treated samples with the untreated infection control. Cytotoxicity assay:

HFF were cultivated in 48-well plates until contluency was reached. Antiviral compounds were added and cells were incubated at 37°C for 7 days, before a measurement of the lactate dehydrogenase (LDH) activity in the residual cell layer was performed by use of the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). For this, culture media were removed, and cells were rinsed with PBS and lysed in a concentration of the kit lysis buffer (100 ml per well). After incubation for 45 min at 37°C, the cell debris was removed by centrifugation and 10 ml of each lysate was diluted in a total of 50 ml of PBS for the determination of LDH activity. Fifty microliters of substrate mix was added to each well and incubated for 30 min at room temperature in the dark. Thereafter, 50 ml of stop buffer was added, and the color reaction was quantitated by use of an enzyme-linked immunosorbent assay (ELISA) reader (optical density [OD] at 490 nm).

11SV virus neutralization assay:

Neutralizing activities of the antiviral compound were determined by endpoint dilution assay as described previously (Krawczyk A. et al., J Virol. 201 1 ;85(4): 1793-803). Briefly, one day before infection. Vcro cells (2 x 10 ⁴ per well) were seeded into a culture plate in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated FBS, 100 U/rnl penicillin and 100 ^πιΐ streptomycin. Next day, serial dilutions of Aciclovir (Ratiopharm, Ulm, Germany) or compound 5 (3-400μΜ) in Dulbecco ^' s modified Eagle's medium (DMEM) supplemented with 2% heat-inactivated FBS, 100 U/nil penicillin and 100 g/ml streptomycin were incubated with 100 TCID ₅₀ of HSV-1 F, HSV-2 G or an Aciclovir- resistant clinical isolate for 2 days at 37°C on Vero cell monolayers. After two days, cell cultures were screened for plaque formation. The drug concentration required for reducing virus-induced cytopathic effect (CPE) by 100% was determined as the complete

neutralization titer.

For control purposes, virus without Aciclovir/compound 5 or Aciclovir/compound 5 alone, respectively, were used to induce maximal CPE and no CPE, respectively. Virus

neutralization assays were repeated at least twice with similar results.

The following HSV-strains were used: HSV-1 F: Herpes simplex virus type 1 , strain F: Aciclovir-sensitive wild-type lab strain. HSV-1 RIO: Herpes simplex virus type 1, clinical isolate: shows resistance to Aciclovir,

Foscarnet and Cidofovir.

HSV-2 G: Herpes simplex virus type 2, strain G: Aciclovir-sensitive wilde-type lab strain. HSV-2 R6: Herpes simplex virus type 2 clinical isolate: Aciclovir-resistant.

The results are shown in the following tables, wherein an X marks plaque format ion and thus cell lysis by viral infection, whereas an empty space indicates absence of cell lysis and thus virus neutralization :

Table l a: HSV- 1 F vs. Aciclovir

Table 2b: HSV-l R.10 vs. C d. 5

Table 3a: HSV-2 G vs. Aciclovir

Table 3b: HSV-2 G vs. Cpd. 5 Table 4a: HSV-2 R6 vs. Aciclovir

Table 4b: HSV-2 R6 vs. Cpd. 5

It is shown that, in addition to Aciclovir-sensitive strains, compound 5 is able to neutralize Aciclovir-resistant HSV-1 and HSV-2 strains.